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 ABSTRACT  
 
TITLE OF THE ABSTRACT;– 
A prospective study to compare T2 W MRI to CT imaging in volume delineation for 
radiotherapy planning in carcinoma cervix  
DEPARTMENT                              : RADIOTHERAPY 
NAME OF THE CANDIDATE      :Dr.APARNA.M.P. 
DEGREE AND SUBJECT          : MD, RADIOTHERAPY 
NAME OF THE GUIDE          :Dr.SUBHASHINI JOHN 
OBJECTIVES - To compare magnetic resonance imaging (MRI), computed tomography (CT), 
and clinical examination to evaluate the impact of MRI on target volume delineation as compared 
to the volumes obtained on a CT scan and also to see the effect on staging and prognosis. 
METHODS- Twenty patients diagnosed with locally advanced carcinoma cervix 
underwent planning CT abdomen and pelvis which was fused with T2 weighted MRI 
images to evaluate the impact of MRI on target volume delineaton , to see if CT scan 
along with clinical findings can be a good alternate to MRI scan.A descriptive analysis 
and frequency distribution of the patient characteristics was done. Fisher's exact test was 
done to find out relationship between prognostic factors and image findings. PABAK was 
done to compare different imaging modalities (CT versus MRI).Paired T test was used 
for tumor volume comparison. 
RESULTS -MRI was better in tumor delineation as compared to CT scan.  Additional 
imaging gave information regarding local extent of the disease, nodal involvement .  
Upstaging of disease helped in selecting appropriate treatment modality. Conclusion-
Though the findings on CT, MRI, or PET examinations are not mandatory for FIGO 
staging it could be of additional benefit and provide extra information that would result in 
stage migration, help appropriate selection of  treatment modality,result in more accurate 
radiotherapy treatment planning and also provide prognostic information that would 
impact on the outcome of treatment and survival. CT with good clinical examination 
could be used as an alternate to MRI where MRI is not feasible.  
Key words- MRI, CT, carcinoma cervix, staging and Radiotherapy planning. 
 
 
 
 
 
 
 
 
 
 
 
 
1. AIM OF THE STUDY 
 
Primary objectives: 
The investigational imaging MRI will be compared with CT imaging to 
• -Compare the target volume delineation and evaluate the impact of MRI on target volume 
as compared to the volumes obtained on a CT scan -  
 GTV Primary (Cervical tumour, involvement of uterus, vagina and parametrium) 
 GTV Lymph nodes 
• To determine whether there is any change in the staging of the disease  
• To determine any change in management or prognosis depending on the extra 
information. 
 
Secondary objective:  
• To see if CT scan along with clinical findings can be a good alternate to MRI scan 
• To look at the possibility of reduction in treatment volume 
• To evaluate the possibility of avoiding  invasive procedures like cystoscopy  
based on MRI/CT findings 
 
 
 
 
 
 2. INTRODUCTION 
 
Cervical cancer is a major health problem in developing countries like India .Appropriate 
evaluation of disease extent and staging is important as this has an impact on the 
management, prognosis and outcome. 
The International Federation of Gynecology and Obstetrics is the most commonly used 
staging system for carcinoma cervix. Since the staging system should be uniform and 
feasible at all centres and also allow for comparison of results from different centres, 
FIGO has recommended staging to be based on clinical findings which  includes 
assessment of the tumour extent (ie, extent of local disease, tumor size, involvement of 
cervix, vagina, parametrium and extent into adjacent normal tissue like rectum and 
bladder)along withlimited radiological investigations which does not include MRI and 
CT scans for staging in carcinoma cervix. Clinical staging may be adequate forevaluating 
local disease extent, but does not take in to account involvement of the uterus, lymph 
nodesor distant metastasis.It has been reported in literature that MRI is superior to CT 
scan and clinical examination for assessing the tumor and involvement of the uterine 
body. 
As patients with carcinoma cervix belong to the lower socioeconomic strata where 
MRI/CT is not feasible and also as MRI/CT may not available in all centers it is not 
possible to do these routinely for staging and management.Hence evaluation in the form 
ofless expensive imaging and thorough clinical examination would be a good 
alternatethat could be carried out.Though the findings on CT, MRI, or PET examinations 
are not mandatory for FIGO staging itcould be of additional benefit and provide extra 
information that would result in stage migration, help appropriate selection of treatment 
modality (surgery/chemo-irradiation/chemotherapy), and will result in more accurate 
radiotherapy treatment planning and also provide prognostic information that would 
impact on the outcome of treatment and survival. Prognostic factors likestage at 
presentation , tumor diameter, tumor volume,lymph node metastasis,lymphatic vascular 
space invasion,deep stromal invasion, microscopic evidence of parametrial invasion , cell 
type and haemoglobin level, have an impact on survival .Therefore the revised FIGO 
staging 2009 has included imaging with MRI in addition to clinical staging where 
resources permit. 
In patients with carcinoma cervix,CT scan   is  primarily used  to evaluate the size of the 
tumor  to detect enlarged lymph nodes, obstruction of the ureter, and  any distant metastases 
to  lung or liver.MRI  has got better soft tissue contrast resolutionthan CT scan and has the 
capability of acquiring images in  multi planar  dimension. It is useful in determining the size 
of the tumor and in detecting parametrial invasion, bladder and rectal invasion .It also helps 
in assessing the presence of enlarged lymph nodes, obstruction of the ureter, and to detect 
lung or liver metastases. 
The aim of radiotherapyis to get adequate tumor control with minimum acceptable amount of 
toxicity. The factors like tumor size, tumor extension and radiotherapy technique used 
significantly affect radiation treatment in carcinoma cervix  
Conventional radiation therapy with four field box techniquehas been used for treating 
patients with locally advanced carcinoma cervix. This technique was designed according to 
bony land marks and better compared to AP-PA technique,with lateral portals designed to 
shield the rectum and small bowel in order to reduce the dose to these organs at risk. Despite 
its proven efficacy and safety this technique has some shortcomings. Many studies has 
showninadequate coverage and chance of geographical miss in conventional methods when 
this was assessedwith cross sectional imaging modalities like  computed tomography (CT) or 
magnetic resonance imaging (MRI).The aim of this study  is to evaluate the impact of MRI 
on target volume delineation as compared to the volumes obtained on a CT scan and  to see if 
CT scan along with clinical findings can be a good alternate to MRI scan. To look at the 
possibility of reduction in treatment volume and to evaluate the possibility of avoiding 
invasive procedures like cystoscopy based on MRI/CT findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. REVIEW OF THE LITERATURE 
 
3.1 Epidemiology 
 
 World wide, uterine cervical neoplasm is the third  most common malignancy in women  
after breast and colorectal cancers (2). According to the SEER data in US , an 
estimated   incidence of  12,340 women and mortality of 4,030 women  with cancer 
of the cervix uteri  is predicted in 2013 . The age-adjusted incidence rate was  found 
to be 7.9 per one lakh  women per year for all races and 6.6 per one lakh  women for 
Asian /Pacific region .(3) 
Compared to western countries there is increase in  cervical cancer incidence in Asian 
countries  including India .Low socioeconomic status and lack of screening programs 
may attribute to this.  
In India ,cervical cancer is the most common malignancy in women. The age-adjusted 
incidence rates  for cervical cancer was found to be  varied from 10.9 to 65.4 amongst 
various registries during the year 1990-1997.  Most of our patients   present  with  
advanced stage of disease .(4) 
In Chennai relative proportion of cervical cancer is found to be 18.5% of all cancers in 
females, with crude  ratio of  20.3 and age adjusted  ratio  of  22.3  incidence rates per 
100,000 person   (ICMR- population based cancer registry-Chennai) 
 
 
3.2 Anatomy 
 
The uterus is a muscular hollow organ located in the mid plane of the true pelvis. It is 
situated  behind the bladder and in front of the rectum ,usually in an anteverted position. 
 Uterus is partially covered by peritoneum in its fundal portion and posterior aspect.  The  
anterior surface is related to the bladder and  lateral surfaces are related to  the broad 
ligaments. The corpus is separated from the cervix by a subtle constriction  which is 
called the isthmus. Cervix is further  divided into two regions based on the ring 
containing the endocervical canal,  into  supravaginal portion   which is above and  the 
vaginal portion, which is projecting in to the vaginal vault. (Fig.1) 
 
 
The uterus is attached to the surrounding structures by means of  2 pairs of ligaments, 
called the broad and the round ligaments . Broad ligament extends from the lateral 
margin of the uterus to the lateral wall of the pelvis  and it  is  made of double layer of 
peritoneum. It enclose the parametrium as it reaches the uterus and it also contains the 
fallopian tubes. The broad ligament follows the plane of the pelvic floor  inferiorlyand 
ends in the upper portion of the vagina, medially. 
 
The round ligament is a  band of smooth muscle and connective tissue , which extends 
forward horizontally from its attachment in the anterolateral portion of the uterus to the 
lateral pelvic wall ,later it crosses the pelvic brim and extends laterally to reach the 
abdominoinguinal ring, finally terminates in the superficial fascia. It contains small 
vessels and nerves.  
 
The uterosacral ligaments traverse  along the recto-uterine-peritoneal fields  and gives 
support mainly for the lower uterus . The cardinal ligaments, other wise known as 
Mackenrodt's ligaments  are thickened connective tissue and fascia arising at the upper 
lateral margins of the cervix and which inserts into the fascial covering of the pelvic 
diaphragm. 
 
The  rich lymphatic network of uterine cervix , drains mainly  into the adjacent  
paracervical lymph nodes and later to  the external iliac which includes  obturator nodes  
and the hypogastric lymph nodes. These  pelvic lymph nodes  mainly drain into the 
common iliac and from there to the para-aortic lymph nodes  (Fig.2). Some of the 
lymphatic channels  from the funduspass laterally across the broad ligament  along the 
ovarian vessels into the para-aortic lymph nodes and some of them  drain into the 
common iliac lymph nodesthrough the external and internal lymphnodes. 
 
3.3 Histology 
 
 Most common histology seen in  uterine cervical malignancies are  squamous cell 
carcinomas  (80-90%). Adenocarcinomas are increasing in incidence and are commonly 
of endocervical type . Anaplastic small cell tumors are aggressive tumors and they have a 
bad prognosis with less than 50 per cent survival rate for stage I disease. Lymphomas  
and melanomas are  rare presentations. Metastases from colon and breast and direct 
spread from uterine malignancies are also seen. 
 
3.4 Risk factors 
 
  Infection with human papillomavirus (HPV),   is postulated as  the main  etiologic agent 
for the main histological subtype of cervical carcinoma, the squamous cell carcinoma and  
its  preinvasive disease (5).  The factors  associated  with an increased risk of acquiring or 
having compromised immune response to HPV infection includes 
Early onset of sexual activity –  The  risk is approximately 1.5 times more  for those who 
are 18 to 20 years   old and   it is two times more for whom those are younger than 18 
years   when compared to those who had first intercourse  after 21 yrs or old. 
Multiple sexual partners –risk is approximately two times more  with two partners and 
three  times more  with 6 or more partners when compared with one partner. 
A  partner withacquired  human papillomavirus infection and other  sexually transmitted 
infections like Chlamydia trachomatis and  genital herpes  or with multiple sexual 
partners is also high risk for developing carcinoma cervix. 
Past history of vulvar  and vaginal squamous intraepithelial neoplasia or cancer  is high 
risk factor as the  etiology  is same in all these conditions  
Any form of immunosuppression is associated with an increased risk  (eg, human 
immunodeficiency virus infection) 
It has been shown that cervical cancer is less common in sexual partners of circumcised 
males . 
 Younger age at the time of first birth (younger than 20 years old) and multiparity (3 or 
more full term births) are also associated with an increased risk of cervical cancer,  as 
these are  associated with increased risk of exposure to HPV through sexual intercourse . 
Studies has shown that low socioeconomic status is also contributing to an 
increasedincidence of cervical cancer.  
Increased risk of cervical cancer has been reported with usage of oral contraceptive pills . 
 
3.5Natural history and patterns of spread 
 
Squamous-cell carcinoma of the uterine cervix usually originates at the squamous 
columnar junction. In  majority of patients the lesion  begins with severe cervical 
dysplasia and carcinoma in situ, later progressing to invasive carcinoma over 10 to 20 
years . As the lesion advances it breaks through the basement membrane and  invades the 
cervical stroma. The chance of lymphatic spread to pelvic and paraaortic nodes increases 
with increase in the  the depth of stromal invasion . The malignant process   later 
manifests as either superficial ulceration or  exophytic growth in the ectocervix and in the 
endocervix  it often presents  as diffuse infiltration of endocervical region .  If left 
untreated, the lesion has the potential to  spread to the adjacent vaginal fornices, 
paracervical and parametrial tissues and  direct invasion of the adjacent structures like 
bladder and  the rectum.Multiple studies has shown thatlocal l extension  is often 
associated with the depth of stromal invasionand  presence of  lymphatic invasion, which 
in turn leads to  lymph node metastasis 
The lower uterine segment and the endometrial cavity involvement by uterine cervical 
cancer can occur in 10% to 30% of patients ,and these patients have more chance  of 
distant metastases . Regional lymphatic or hematogenous spread occurs, depending on 
the stage of the tumor, but dissemination does not always follow an orderly sequence. 
In  a study conducted by Girardi et al, incidence of parametrial nodes were found high 
78% patients  out of  359 specimens of radical hysterectomies. Sub analysis showed ,only 
26% of patients had positive iliac lymph nodes in the absence of parametrial nodes. All 
these data supports  the need for a complete bilateral pelvic lymphadenectomy in patients 
with invasive cervical carcinoma or  irradiation of  parametrial tissues in patients 
undergoing radical radiotherapy.Regional lymph nodes includes, the nodes in the 
parametrium, external iliac nodes including obturator nodes,  internal iliac nodes and 
common iliac nodes were commonly involved in patients with  locally advanced  
carcinoma cervix .  Para-aortic lymph nodes were  found to be involved in3/91 (3.3%) 
patients with stage IB and IIA tumors and in 5/38 patients (13.1%) with stage IIB and III 
disease. 
Increased depth of stromal invasion is associated with increased risk of pelvic lymph 
node metastasis, according to the International Federation of Gynecology and Obstetrics 
(FIGO) staging system. It is estimated to be around 0.2  -0.6 % for stage IA1 disease and 
7 % for stage IA2 disease. 
 
There is an increased risk of  paraaortic nodal involvement in addition to pelvic nodal 
disease as the extend of local disease increases,, 8 %,12 %,29 % 17 % and 27 % 
respectively for stage IB,stageIIA, stage IIB, stage IIIA and stage IIIB disease. 
 
 
 
3.7  FIGO staging for carcinoma cervix 
 
Staging of cervical cancer is one of the oldest staging in the literature, dating back to 
1928. Classification of  Carcinoma of the Uterine Cervix is done by International 
Federation of Gynecology and Obstetrics (Appendix I). Since the initial staging was 
introduced by them,    2 revisions  has done in 1988 and 2009.  The controversies 
surrounding cervical cancer staging has contributed to  revision in 2009 and published in 
International journal of gynecology and obstetrics which is the official organ of the 
FIGO.Since the staging system should be uniform and feasible at all centres and also 
allow for comparison of results from different centres, FIGO has recommended staging to 
be based on clinical findings which  includes assessment of the tumour extent (ie, extent 
of local disease, tumor size, involvement of cervix, vagina, parametrium and extent into 
adjacent normal tissue like rectum and bladder)along with limited radiological 
investigations which does not include MRI and CT scans for staging in carcinoma cervix. 
Clinical staging may be adequate forevaluating local disease extent, but does not take in 
to account involvement of the uterus, lymph nodesor distant metastasis. 
 
3.8  Prognostic factors 
 
A retrospective analysis undertaken by Kapp et al, in an attempt to identify prognostic  
pretreatment  factors showed that FIGO stage is an important prognostic factor (6,7) 
.Other factors like  patient ,s age at diagnosis, , histology,  pretreatment haemoglobin 
level and  neutrophil count   , co morbid illness like  diabetes mellitus and  history of 
multiple number of pregnancies are found to be associated with prognosis. It was found 
that increased tumor size (8) was associated with decrease disease-free survival and local-
regional control rates, when all other factors including stage was controlled for.  The 
diagnosis of pelvic lymph node metastasis is an important prognostic factor  in patients 
with uterine cervical cancer (9,10) as it adversely effects out come. Some of the studies 
which have reported prognostic factors and is suggested to be included in the staging 
system are depth of stromal invasion (11-16), tumor size, presence or absence of 
lymphatic vascular space invasion (17-24), pelvic lymph node status (25,26), tumor 
volume, endometrial extension of cervical carcinoma, and parametrial involvement. 
Other patient factors which have been extensively studied are the age and the 
socioeconomic factor. Medical factors include anemia, tumor hypoxia , arterial 
hypertension, fever and  HIV infection. 
When we consider lymphatic spread and the various types of histology, positive lymph 
nodes are found in adenocarcinoma more  than in squamous cell carcinoma, showing the 
difference in their behavior. It was  found by Korhonen et al that there is no significant 
difference in survival rate between pure adenocarcinoma  with other subtypes like  
adenosquamous carcinoma and  clear cell adenocarcinoma (27) . Histologic type and 
grade of  thetumour also has an impact on survival to a lesser extent.  
Prognostic factors based on imaging -There are data showing that the size of the cervix  
evaluated in CT scans is directly proportional to  local control and overall survival 
(28,29). In a retrospective study of CT scans done on cervical cancer patients by 
Shepherd et al showed that tumor depth was correlated with lymph node 
involvement(30) 
Based on MRI volume Kodaira et al showed that 5 year DFS of patients treated with 
radiotherapy with tumor diameter more than 5 cm was significantly lower (46.2%) than that 
for patients with size less than 5cm.(88%)  (31) .MRI dynamic enhancement during the first 
2 weeks of radiation therapyhas shown  early prediction of tumor regression rate( 32).MRI 
studiesconducted  by Hantano et al at 30 Gy of external radiation and 3 months after 
radiation therapy were predictive of local tumor control.(33) 
Tumor with cranio -caudal diameter,(which was obtained by measuring the length of the 
tumor parallel to the long axis of uterine body )    lessthan or equal to4 cm  was  associated 
with better five-year disease-free survival ( 70%) compared to patients with tumor diameter  
more than 4 cm.(34) 
Study   by Toita showed  that  antero posterior diameter (AP) of  tumor   more than4 cm  
was associated with increased incidence of lymph node metastasis and  distant 
metastasis(35) 
In another study by Kodaira et al, showed  large tumor size (volume  more than 50 cm3 
)and positive lymph node enlargement  showed a significantly unfavorable influence on 
survival and local and  distant failure (p < 0.05) (36) 
Recently, Kim et al( 37) showed  lower ADC in metastatic lymphnodes  (0.7651 × 10−3 
mm2/sec) than in non metastatic lymph nodes (1.0021 × 10−3 mm2/sec). 
MRS study has shown that lactate level in cervical cancer tissue correlated with more 
chance of  metastatic spread . There was  higher levels of cholines and amino acid residues 
and lower levels of glucose in malignant tissue of the cervix when compared to  
nonmalignant tissue ..(38) 
Another biomarker is ADC histogram analysis which has proven its efficacy in predicting 
tumor recurrence in patients treated with chemoradiation. (39) 
 
3.9 Staging and workup 
 
It is advisable that all patients with carcinoma cervix should be jointly evaluated by the 
radiation and gynecologic oncologist. Detailed history and physical examination of the 
patient including a pelvic examination should be done. Special attention to the supra 
clavicular nodal areas ,per abdomen findings for hepatomegaly, tenderness  in 
hypogastrium or renal angle  tenderness and inguinal area examination for any palpable 
lymph nodes should be carried out. Pelvic examination should include inspection and of 
external genitalia, vagina and uterine cervix  and rectal examination and bimanual 
palpation of the uterus and adnexa with special emphasis on parametrial involvement. In 
all patients with stage IIB and more advanced disease and in those patients who gives a 
history of urinary or lower gastrointestinal tract complaints cystoscopy or rigid 
rectosigmoidoscopy is recommended to rule out local infiltration. 
Staging of Carcinoma of the uterine cervix is managed by means of the International 
Federation of Gynecology and Obstetrics (FIGO) staging system. The FIGO staging 
system is determined mainly by the clinical assessment. This was seen to be quite 
sufficient for early stage disease, but it has limitations in assessing advanced stage 
disease. It does not take into account the nodal involvement. Though not routinely used in 
the developing countries, CT and MR imaging are widely used elsewhere to evaluate 
tumor size and extent, and nodal involvement. In this it was found that MR imaging is 
excellent for depicting invasive cervical carcinoma with objective measurement of tumor 
volume. It rules out conclusively parametrial invasion and stage IVA disease. 
The following investigations are recommended for the work up of carcinoma of cervix, 
by FIGO. 
 
Diagnostic work-up for carcinoma of the cervix 
 
General *History 
*Physical examination, including bimanual pelvic and rectal 
examinations 
Diagnostic procedures *Cytological smears(Papanicolaou) if not bleeding 
*Colposcopy 
*Conization (subclinical tumor) 
*Punch biopsies (edge of gross tumor, four  quadrants) 
*Dilatation and curettage 
*Cystoscopy, rigid rectosigmoidoscopy(stages IIB, III, and 
IVA 
Radiographic Studies Standard 
  *Chest radiography 
  *Intravenous pyelography 
  *Barium enema (stages III and IVA and earlier           stages 
if there are symptoms referable to colon or rectum)  
Complementary 
   *Lymphangiography 
   *Computed tomography (CT) or magnetic resonance 
imaging (MRI) 
   *Positron emission tomography (PET) scan(optional) 
Lab tests    *Complete blood count including manual      platelets 
   *Biochemical evaluation including LFT and RFT  
   *Urine analysis 
   *blood born virus screening 
 
 
3.9 Role of imaging in the management of carcinoma cervix  
 
Imaging used in oncological setting should be capable of differentiating between 
malignant and non malignant tissues at all stages . These imaging techniques helps in  
staging  of disease  accurately and also have a role in the  delineation of the target 
volumesfor planning radiation therapy.  The  idea about extent of the tumor influence 
therapeutic decisions, therapy outcomes and thus patient prognosis. 
Chest Xray 
Standard chest radiographs  are recommended to  evaluate the lungs for metastases  
 
Intravenous pyelograms 
 
Intravenous pyelograms  are used to evaluate  the kidneys for ureteral obstruction.  
 
Barium enemas  
Barium enemas and and X-rays are allowed in staging ,but are more helpful in  patients 
with bulky tumors as part of staging and  treatment planning. 
 
Lymphangiography. 
 
1961, Wallace et al demonstrated that Lipiodol  a dye can  demonstrate the structure of  
metastastic nodes . People then started doing lymphangiography to detect  lymph node 
metastases in patients with cervical cancer.It is  performed by direct cannulation  and  
injection of contrast agents into the lymphatic ducts. It will penetrate lymph nodes and  
normal lymph nodes appear opaque on film.  The  lymph nodes which contains metastatic 
cellswill not become opaque after the injection of contrast material.  The size of a lymph 
node as well as the internal architecture can be demonstrated  by   lymphangiography  
and it can also detect abnormalities within a normal-sized lymph node on other imaging. 
Its specificity is more than sensitivity ,which was found to be ranging from 47% to 100% 
False-negative results may occur in the presence of microscopic metastases and false-
positive results can occur in case of  fatty infiltration and inflammatory processes.   
 
Following bipedal lymphangiography in carcinoma cervix patients , the external 
iliac, common iliac, and retroperitoneal lymph nodes are seen as opaque. The contrast 
material remains in the lymph nodes for several months, will be useful for the 
localization of nodes at the time of  radiation treatmentplanning. 
However, the procedure is invasive and  difficult to perform. 
Ultrasonography 
Ultrasound   generated by piezoelectric materials  is a form of  non radiation exposure 
imaging modality. In gynaecological practice , both trans abdominal and trans vaginal 
ultrasonography are commonly used  . Ultrasonographic evaluation in carcinoma cervix 
patients helps in assessing cervical size, enlarged pelvic or para aortic lymph nodes and 
hydrouretero nephrosis or liver metastasis. .Many of the studies using TransRectal 
UltraSonography (TRUS) has shown benefit in the evaluation of  tumor size and also in  
parametrial involvement. Innocenti et al.(39) reported  for  83 % staging  accuracy   with 
TRUS, compared to physical examination 
 Magee et al.(40)evaluated correlations between  tumor size measured by TRUS and 
overall survival. Gitsch et al.(41) reported that stromal reaction detected in  TRUS  have 
high specificity for  diagnosing parametrial invasion . Cobby et al.(42) reported  when 
compared to  clinical examination and MRI ,accuracy rates of 95% for   Transrectal 
ultrasound (TRUS),which is relatively a cheap investigation . It has shown efficacy  in 
the evaluation of early parametrial infiltration ,tumor volume , and  even  of identification 
of residual tumor in early-stage cervical cancer as compared to MRI(43). 
 
 
Imaging modalities like  computed tomography and magnetic resonance imaging detects 
cancer by identifying anatomical distortion or altered tissue appearance. Administration 
of  intravenous contrast medium enhances delineation. With the emergence of functional 
imaging like diffusion weighted imaging and PET CT it is possible to more accurately 
define the tumor , monitoring treatment response and to make out relapsed disease when 
compared to conventional imaging techniques. 
MRI and CT SCAN: 
1.Tumor size and local spread - If imaging is considered, MRI is the modality of 
choice.In a prospective study included 208 women, most with stage IB disease, who 
underwent MRI and CT prior to surgery [44]. MRI correlated more closely with 
surgicopathologic findings than CT or physical examination. An important observation 
from this study is that ,  overestimation of tumor size in all imaging modalities.Over 
estimation of findings in surgical candidates may not change treatment or prognosis, 
while underestimation of size can potentially triage a patient to surgical excision where 
chemoradiation is the treatment.  
MRI is more helpful in the assessment of extra cervical tumor  extension(45).It is a useful  
imaging modality in patients allergic to iodinated contrast or impaired renal function. 
Any way it is contraindicated in patients with pacemakers, cochlear implants ,metallic 
prosthesis or large vascular clips .On T2 weighted images  a cervical cancer may be seen 
as a mass usually of greater intensity than  fibro cervical stroma  .  Parametrial invasion is 
easily identified on  T2 –weighted images from low intensity cervix and uterine 
ligaments. MRI was superior to CT scan in localizing the primary site. MRI is  shown  
superiority ove CT scan  in detection of  parametrial extension and invasion of 
surrounding structures .It has limitation in detecting lymphnodes .and  false positive 
results can occur because of  volume averaging with bowel (46). 
Estimating the presence of parametrial spread is also of critical importance for deciding 
whether patients are candidates for surgical treatment.Results from multiple studies are 
controversial, whether imaging studies are better able to detect parametrial spread than 
clinical staging [47-50]. Imaging studies performed better than clinical staging in one 
study, a prospective multicenter study of 172 women with cervical cancer who were 
clinically staged as IB or higher underwent CT and MRI prior to surgery [47]. Detection 
of stage IIB or higher was poor for all approaches, but imaging studies performed better 
than clinical staging: clinical staging (sensitivity: 29 percent and specificity: 99 percent); 
CT (42 and 82 percent); and MRI (53 and 74 percent). In contrast, a retrospective study  
byHancke K et al found clinical staging to be superior to CT and MRI [50]. In that study, 
the sensitivity and specificity for detection of parametrial involvement (stage IIB) was: 
clinical staging (sensitivity: 66 percent and specificity: 81 percent); CT (43 and 71 
percent); and MRI (52 and 63 percent).  
MRI was found to be superior to CT for evaluation of parametrial involvement in a meta-
analysis of 57 studies ,byBalleyguier C  et al  ( 51,52) 
There are limited  data regarding the use of PET/CT for the evaluation of tumor size or 
local spread in cervical cancer (53) 
The scope of MR spectroscopy in cancer cervix has gained attention in the recent years to 
establish their role as predictive biomarkers. MRS Studies have shown that ADC and total 
cholinelevel  was different between different histological  types of cervical  cancer.(54) 
 
2.Lymph node metastases — Cervical cancer may spread to the pelvic or Paraaortic 
lymph nodes, as well as more distal nodes. The presence of lymph node involvement is 
associated with a worse prognosis and impacts decisions regarding the radiotherapy field 
(55) . Parameters   like short axis  diameter, roundness index , irregular outline and extra 
capsular spread  are used  for evaluation of enlarged lymphnodes  based on different 
imaging modalities. Ultrasonography can make out presence or absence of hilar 
structures ,any alteration in cortical structures and presence of microcalcification or 
necrotic areas. Where as CT scan detects presence of necrosis as hypodense areas  and 
metastatic nodes show nonhomogenous enhancement following intravenous contrast 
administration. 
Metastatic nodes also show inhomogenous enhancement following Gadolinium 
administration in MRI . Nodes are seen as inhomogenous signal in T2 weighted images, 
intensity will be unchanged after USPIO administration in  T2 weighted sequences and 
hyper intense areas in T2 weighted sequence shows the presence of necrosis. 
The overall accuracy of CT scan in staging cervical cancer ranges from 63% to 
88%.(56).The accuracy  of CT scan in detection of lymphnode is found to be  77% 
to85%. With a sensitivity of 44% and specificity of 93%.(57). In his study by Camelion, 
it was shown that  CT scan is more useful in the detection of Para-aortic nodes with a 
sensitivity of 67% and specificity of 100%. 
Initial evaluation of lymph nodes is commonly performed with CT to minimize expense, 
but PET and PET/CT are the imaging modalities used to provide information for 
treatment decisions. These studies have largely replaced MRI and lymphangiography . 
Integrated PET/CT imaging is a technique in which both PET and CT are performed and  
images are fused using software.This  gives additional information of  physiologic 
activity seen on PET along with the anatomic localization on  CT images. 
Studies has shown the superiority of PET to other imaging modalities.In a meta-analysis 
of 72 studies including 5042 women with cervical cancer,imaging modalities were 
compared  for the detection of lymph node metastases sensitivity and specificity of  PET  
was  75 % 98 % ,when compared to  MRIand CT  [58]. Integrated PET/CT may be more 
sensitive than PET alone for detection of nodal metastases, particularly for pelvic lymph 
nodes [59-61].  
However,in locally advanced cervical cancer, PET/CT may have a higher false-negative 
rate for detecting Paraaortic lymph node spread . In a study of 60 patients with stage IB2 to 
IVA disease found that 12 percent of those with no finding of positive Paraaortic nodes on 
PET/CT findings had pathologically positive Paraaortic nodes [62]. A subset of patients with 
PET/CT findings of positive pelvic and negative Paraaortic negative nodes had an even 
higher rate of pathologically positive Paraaortic disease (22 percent). In a separate study of 
PET/CT and pathologic analysis of Paraaortic nodes, patients with PET positive pelvic and 
negative Paraaortic negative nodes had a similarly high unrecognized disease to Para aortic 
nodes (24 percent) [63]. 
  Recent studies done  for comparison of imaging and histology in the diagnosis of 
metastatic lymph nodes  imaging showed poor sensitivity of CT (24%; ), MR (29%), and 
even PET (58%;). This was postulated to be due to  inaccuracy in detecting lymph nodes 
which harbor cancer cells.Routine crieteria used for detecting  metastatic lymphadenopathy 
by measuring  short  axis diameter (SAD)which  is said to be significant if  SAD greater than 
1 cm. Recently, Kim et al( 64) showed that the apparent diffusion coefficient was  lower in 
the metastatic lymph nodes. Diffusion weighted images gives additional information 
regarding   ADC  .It has advantages over other routine imaging modalities in the detection of 
metastatic lymph nodes as it is  independent of size of the node.  
 
3.Bladder and rectal infiltration by uterine  cervicalcarcinomas — Tumor extension to the 
bladder and ureter may result in hydronephrosis and, ultimately, in nonfunctioning 
kidney in women with cervical cancer. The urinary tract is imaged in all patients with 
more than a microscopic tumor. While intravenous pyelography (IVP) is the examination 
included in the guidelines for clinical staging, MRI and CT  are typically used where 
available .IVP still has a role in  low resource settings. 
Trans vaginal ultrasound is another investigation of choice for ruling out bladder 
infiltration, where  echogenic boundary between the cervix and  posterior bladder wall is 
intact. 
In a retrospective study by Krestin GP, Hauser M et al, where they compared 6 different 
imaging signs of focal bladder infiltration in 129 patients who underwent 92 CT and/or 
64 MRI examinations. These findings  were later correlated with cystoscopy, rectoscopy  
,intraoperative findings and histological examination of surgical sections (65).In 27 
patients submitted to both imaging examinations  it was found that  MRI provided similar 
results as endoscopic procedures like  cystoscopy and rectoscopy .Subset analysis showed 
that MRI was superior to CT scan. This study showed that Imaging  can predict  bladder 
or rectalwall  infiltrationin carcinoma of the uterine cervix and can avoid  endoscopic 
procedures. 
In another study MRI 5 point scoring system was done to rule out bladder and rectal 
infiltration and score of 3 or above were used to identify patients with bladder and rectal 
infiltration (66). This study showed that MRI  scoring system predicts local infiltration of 
bladder and can safely avoid the need for invasive cystoscopic or endoscopic procedures 
in the majority of patients with cervical cancer. This   leads to a reduction in morbidity 
associated with these procedures. 
4.Response assessment to treatment –To assess disease status on follow up evaluation . 
Recommendation mentioned earlier under ABS guidelines. 
 
 
 
5. Diffusion –weighted MRI  imaging in pelvic malignancies 
Stejskal and Tanner in 1965 described diffusion –weighted sequence as an advanced 
methodof  T2 – weighed sequence. Itprovides  bothqualitative and quantitative 
information about structural  tissue changes at cellular level. 
Diffusion weighted imaging  uses the principle of  exploitation of water movement in the 
intracellular  as well as  extracellular spaces .  The movement of water molecule in an 
unrestricted environment is random and is known as a phenomenon called Brownian 
motion. Within the organ ,the impedence of water molecule diffusion depends upon the 
the extend of tissue cellularity and presence of intact cell membranes . 
Hence those  tissue types  which are associated with tumor, cytotoxic edema, abscess and 
fibrosis will show  impeded diffusion  . 
Mechanism of diffusion –weighted sequence (Kindly refer Fig .1 on annexure) 
The T2- weightedMRI  sequence consists of a 90 degree  followed by a 180 degree 
radiofrequency (RF) pulse and is associated with  T2 decay due to transverse relaxation. 
In diffusion weighted sequence , a diffusion sensitizing  gradient otherwise called a 
dephasing gradient is applied prior to the 180 degree RF pulse followed by  a symmetric  
rephasing gradient after 180 degree pulse.Water molecules movement with in a restricted 
environment cannot move long distance and  the shift obtained within it during the 
application of dephasing gradient will be cancelled by the application of rephrasing 
gradient.This results in no net loss in signal intensity. But if the cellularity of the tissue is 
low,water molecule move long distance and will not get rephrase with second gradient 
and often result in net loss of signal intensity. 
 
 
b value – 
b value is the strength of  diffusion sensitizing gradient .It is measured in seconds per 
square millimeter. It is directly proportional to the amplitude of gradient ,its duration and  
time interval between the gradients. 
At a b value of 0 sec/mm2 (i.e. if there is no diffusion sensitizing gradient) ,the signal 
intensity of the imaged organ will be same as T2 weighted imaging. At high b values 
(500 – 1000 sec/mm2) water movement in those tissues which has highly cellular tissues 
such as   tumor, neurological tissue, normal lymphatic tissue, bowel mucosa and   normal 
endometrium will appear bright on diffusion weighted images. As the  b values are organ 
specific, diffusion weighted images should be tailored accordingly. 
  
Qualitative assessment by means of  Diffusion-weighted imaging- 
Depending on the region or organ which has to be imaged ,diffusion –weighted imaging 
is performed using at least 2 b values ,0 sec/mm2 and 500-1000 sec/mm2. The signal loss 
in different water molecules helps in characterization of the lesion as increased  signal 
intensity at high b value suggests restricted diffusion consisted with highly cellular tissue. 
This interpretation is always compared with other sequences of MRI for final conclusion. 
 
Quantitative assessment of  Diffusion weighted imaging 
It is based on ADC value. When we plot logarithm of signal intensity  versus b values 
,there will be exponential decay of signal  with increasing b values. The  slope of this line 
gives   ADC  value. The ADC values of tumors are usually low as the decay in signal is 
reduced in tissues with restricted diffusion.  Thus quantitative measurement of ADC 
value helps to differentiate malignant lesion from benign lesion based on the low signal 
intensity of malignant lesion on ADC mapping. 
 
Normal cervical stroma  shows low signal intensity on T2-weighted images and delayed 
enhancement on gadolinium-enhanced images as it  contains large amounts of fibrous 
tissue .But as cervical cancer tissue has greater cellularity , it shows higher signal 
intensity on T2-weighted images and greater enhancement on gadolinium –enhanced T1-
weighted images.  
 
Cervical carcinomashows significantly lower ADC as it  demonstrates impeded diffusion 
relative to normal cervical stroma.Many of the studies has shown ADC value of 1.09 +/-
0.2x10-3 mm2/sec  for cervical carcinoma compared to normal cervix 1.79 +/-0.24x10-3 
mm2/sec. The usage  of diffusion weightedimaging  for the characterization of pelvic 
lymph node in gynaecological cancers is not recommended as it has lots of pitfalls. 
 
2. Radiotherapy treatment planningand imaging 
Radiotherapy is the mainstay of treatment in locally advanced  carcinoma of cervix. 
Radiotherapy is delivered  by a combination of external beam photon therapy and 
brachytherapy. External irradiation is used to treat the whole pelvis and parametrium 
including the common iliac  nodes whereas the central disease- cervix, vagina and the 
medial pat of the parametrium is primarily irradiated with the intra cavitary  sources. 
 External beam irradiation 
 It is delivered before intracavitary insertions in patients with a) bulky cervical lesions or 
tumors beyond stage IIA to improve the geometry of the intracavitary application; b) 
exophytic easily bleeding tumors, c) tumors with necrosis or infection, d) parametrial 
involvement 
It is important to deliver the adequate doses of irradiation not only to the primary tumor 
and to the pelvic lymph nodes. The common iliac bifurcation being cephalad to the 
lumbosacral prominence, the superior border of the pelvic portal should be at the L4/L5 
inter space to include all of the external iliac and the hypogastric lymph nodes. This 
margin is extended to the L3/L4 interspace if common iliac nodes are to be covered. A 2 
cm margin lateral to the bony pelvis is adequate. If there is no vaginal extension, the 
lower border of the portal is at the inferior border of the obturator foramen. If the vagina 
is involved, the entire length upto the introitus  should be treated. In patients with tumor 
involving the distal half of the vagina, the portal fields should include the inguinal lymph 
nodes. The anterior border of the lateral field is  kept 3 cm in front of the anterior surface 
of  the L4 vertebral body or at the pubic symphysis and posteriorly at the S2/S3 junction. 
In locally advanced tumors the posterior border maybe extended to include the entire 
sacral hollow. 
 
Previously the  most common technique recommended for irradiation of the whole pelvis 
was the two-field  approach using an A-P/P-A technique . The four-field box technique 
which is commonly used now for conventional planning  was introduced in the early 
1980s .The aim of of this method was to  reduce the volume of normal tissue being 
treated and  to increase the dose to the tumor volume. This technique has two lateral 
portals and one anterior and posterior portals each.The  lateral ports were recommended 
to shield  posterior wall of the rectum,  anterior wall of the bladder and some of the small 
bowel, in order to reduce the dose administered to these critical organs. 
  
In 1993, based on the  lymphangiography examinations, Pendlebury et alreported that  at 
least 2.5 cm margin from the pelvic side wall would be required for adequate coverage of  
pelvic lymph nodes in 90% of patients (67) . Guidelines for the lateral pelvic ports were 
based on the bony landmarks that can be identified radiographically. The commonly used 
field borders for the lateral fields wasanteriorly 3 cm anterior to anterior border of L5 
vertebral body and posteriorly S2/S3 interspace  . Ports defined by these guidelines is not  
always suitable for the individual patient’s anatomy.  Based on intra-operative 
measurements, Greer et al. opined  that the entire anterior sacral silhouette should be 
included in the lateral fieldin patients with locally advanced carcinoma cervix ,due to  
posterior extension of the parametria (68) 
 
Several methods have been made periodically attempted to improve treatment planning 
taking into account  the individual anatomy of the patients .Initially conventional 
radiographic treatment planning using contrast medium in the bladder and rectum were 
tried .The  information  obtained from this method  was limited regarding the localization 
of tumor and uterus.  
 
There after comes the era of computed tomography which  enabledthe visualization of the 
pelvic organs, structures including in the clinical target volume and organs at risk. In a  
prospective study  conducted on 34 patients with cervix carcinoma  Kim et al ,(69)  
simulated  all patients with  conventional four-fieldpelvic portals .Customized blocks 
were used to shield  the posterior wall of therectum and a part of small bowel using the 
barium silhouette of those organs. Following this CT scan was done to identify the tumor 
volume on each slice.It was found that  posterior margin coverage was ranging from 39% 
to 50% only in the conventional as compared to CT  based planning. There were  
inadequate coverage  at the customized rectal block, and in the posterior  border on the 
lateral fields. With a median follow-up of 36 months, it was found that pelvic control for  
inadequate margins was 100% and 71% for stage IB, 88% and 50% for stage IIB. 
 
In 1992Russell et al.,reported the value of pelvic MRI indetermining the lateral fields of 
the four field box technique ( 70).It is proven that  MRI has the additional advantage in 
the  visualization  the anatomy of the pelvis in all the planes .It also provides a  better  
soft tissue delineation  and tumor depiction than CT scan[71-76].From their study, 
Russell and colleagues found that  using the  conventional lateral portals , the tumor 
volume wasadequately  covered  in  only 44% of patients  . There was  incomplete 
coverage of the  uterine fundus in 62.5% and marginal miss in more than 50% of patients.  
In their study Zunino et al. found that due to uterusflexion and associated pathology  like 
myoma, endometriosis and pyometra ,the lateral portals failed to involve PTV in  50% of 
cases(77). 
 Thomas et al  conducted a study in which the  MRI images were acquired in the 
treatment position  using flat table and MR detectable tubing  for marking radiation ports, 
concluded that MRI in treatment position alone could assess the simulated fields . 
All these studies showed that the  potential benefit of the lateral fields to shield the 
rectum and small bowel is outweighed most of the time  by the loss of tumor margins. 
Multiple studies has shown that the most common pattern of regional recurrence (66-
97%) in patients treated with conventional radiotherapy was at the margin of the radiation 
field. Cross sectional images (CT/MRI) helps radiation oncologists to customize the 
external radiation treatment fields based on the findings. Nowadays, the CT based 
simulation has been widely established. The CT simulation helps to include the tumor 
volume inside the treatment fields either treated with conventional technique (AP/PA), or 
advanced techniques such as 3 dimensional conformal radiation therapy (3DCRT), or 
intensity modulated radiation therapy (IMRT)  
3D conformal radiotherapy is the standard of choice for irradiation of 
gynaecological malignancies at present. CT-based 3D planning and mainly the use of the 
beam’s eye view (BEV) helps the physician  delineating the target volumes and organs at 
risk .It helps in the optimal design of individually shaped fields .Thus helps to avoid 
geographical misses  and to reduce the dose to organs at risk . 
Recently, the concept of pelvic radiotherapy using IMRT  has  emerged with its increased  
usage for external radiation treatment. Rationale for IMRT in cervical cancer is based on 
multiple studies .It has shown improved delivery of conventional doses, simultaneously 
achieved with decreased dose to normal tissue like small bowel,bladder,rectum and bone 
marrow  ( 78-80).The concept of bone marrow sparing IMRT has come with benefit of 
reduced haematological toxicity with concurrent chemotherapy(81).It allows dose 
escalation in high risk patients like node positive disease and gross residual disease. 
Simultaneous integrated boost to node positive patients has shown benefits(78) .It has 
also shown reduced dose to normal tissues in extended field radiotherapy (82).The role of 
IMRT to an alternative for brachytherapy was considered in patients with for locally 
advanced gynecological cancers that may not be amenable to brachytherapy for anatomic 
or medical reasons. IMRT with simultaneous integrated boost has shown benefit to 
conventional two-phase treatments (whole pelvic irradiation followed by brachytherapy 
or EBRT boost) due to shorter treatment time, significant sparing to normal structures 
and capability of potential for dose escalation (83). 
Additionally, cervical cancer patients receiving IMRT treatment showed superior cause 
specific and overall survivals compared to patients who were treated with conventional 
radiation therapy (Kidd et al., 2010). 
The target delineation is very important for complicated radiation treatments. Radiation 
doses would be delivered to only the designated targets and avoid the non-designated 
areas. Likewise, the normal tissues may not be spared if these structures are not assigned.  
The implementation of MRI into radiation planning has its limitations mainly due to 
reasons such as distortions and lack of electron density for radiotherapy dose calculation  
(84).MRI  can be  used in the planning system after integrating  tools for CT/MR image 
registration. These registered  images from each modality  are preferably taken with the 
patient in the treatment position  .The MR image helps in  delineation and the calculation 
is often made on CT.  Perez et al (85).Showed that when compared to CT alone 
automatic rigid fusion followed by a deformable soft tissue fusion improves high degree 
of anatomical correlation . 
MRI vs CT in tumor volume delineation 
In a study by . Subak LL, showed that tumor volume was evaluated accurately by MRI,  
when compared to CT and later confirmed by pathological evaluation . Magnetic 
resonance was 88% accurate evaluating the presence of stromal invasion and 78% 
accurate for depth of stromal invasion. Computed tomography could not evaluate tumor 
size or stromal invasion because it could not distinguish cancer from the surrounding 
normal cervical tissue (86). 
A number of publications from The American College of Radiology Imaging Network 
(ACRIN) and The Gynecologic Oncology Group (GOG) have demonstrated that 
traditionalT2-weighted MR imaging is superior to CT for tumor delineation in cervical 
cancer (44). 
 Recent recommendations from GEC-ESTRO have emphasized the role of MRI in target 
delineation for brachytherapy in cervical cancer  (87). 
 
Brachytherapy 
 
Like external radiotherapy, brachytherapy also has progressed from two dimensional 
(2D) planning to three dimensional (3D) planning with the help of new imaging 
modalities. Conventionally, brachytherapy has been planned with the knowledge of 
clinical examination in conjunction with orthogonal radiographs .Treatment was based on 
arbitrary 2D prescription points and normal adjacent organs for dose prescription.  In 
individual patients this 2D method can cause inadequate dose delivery to the tumor  and 
may lead to underestimate the doses to organ at risk. Recently, 3D brachytherapy 
planning using CT/MRI images has become popular, where there is provision to make 
out the residual tumor related to adjacent organs .This in turn   provides adequate dose 
coverage to the primary tumor and surrounding microscopic diseases while reducing the 
dose to the adjacent critical structures 
During the last 10 years, MRI is being used in conformal brachytherapy treatment 
planning  as it provides superior soft tissue resolution compared to CT post external beam 
radiotherapy and  and because electron density does not play a role in dose calculation in 
brachytherapy. The  GECESTRO Working Group and the American Image-Guided 
Brachytherapy Working Group have proposed the use of  T2- weighted MRI  in image 
guided brachytherapy. This images are preferably done using  a pelvic surface coil and  
image-compatible brachytherapy applicators. According to the GYN ESTRO Group the 
GTV for BT (GTVB) includes macroscopic tumor extension at the time of BT as detected 
by clinical examination and as visualized on MRI (high signal intensity mass .High-risk 
CTV for BT (HR CTV)  includes GTVB, the whole cervix, and the extra cervical  tumor 
extension at the time of BT defined by means of clinical examination  and  residual grey 
zones on MRI. No safety margins are recommended. Intermediate-risk CTV for BT (IR 
CTV) carrying a significant microscopic tumor load encompasses HR CTV with a safety 
margin of 5–15 mm depending on the  pretreatment tumor location, tumor size , potential 
areas of microscopic  spread, extend of  tumor regression during treatment and the 
treatment plan(87) 
Adaptive radiation therapy  
The concept of adaptive radiation therapy was generated to take account of target 
changes such as tumor shrinkage and internal organ motions during radiation therapy .  
Image guided radiation therapy (IGRT)  make use of  reconstructed cross-sectional 
images taken during treatment  .It enables the delivery of  radiation doses to the actual 
targets,  to monitor the tumor changes, both intrafraction and interfraction, during the 
external radiation courses. Tumor shrinkage during treatment is a concern and action 
should be taken to monitor changes during the radiation treatment. 
Following table shows comparison of three different modalities frequently used for 
disease assessment in carcinoma cervix patients( ref;Advanced Imaging Applications for 
Locally Advanced Cervical Cancer ,Janjira Petsuksiri et al ) 
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3. 9 Clinical Presentation 
 
Early invasive carcinoma of the cervix can be detected before it becomes symptomatic by 
cytological smears. Sero sanguienous or whitish, foul-smelling vaginal discharge may be 
noted in patients with invasive carcinoma, particularly with more advanced necrotic 
lesions. If chronic bleeding occurs, the patient may -complain of fatigue or other 
symptoms related to anemia. 
Pain, usually in the pelvis or hypogastrium, may be noted and could be caused by tumor 
necrosis ,pyometra or associated pelvic inflammatory disease or urinary tract infection. 
Low back ache is another common presentation. In these cases the possibility of par 
aortic lymph node involvement with extension in to the lumbosacral roots or 
hydronephrosis should be considered. Occasionally epigastric pain may be caused by 
metastasis to high Para-aortic lymph nodes. 
Urinary and rectal symptoms (hematuria , dysuria and rectal bleeding) may appear in 
advanced stages as a consequence of invasion of the bladder or rectum by the neoplasm. 
Diagnostic work-up for carcinoma of the  cervix 
General *History 
*Physical examination, including bimanual pelvic and rectal 
examinations 
Diagnostic procedures *Cytological smears(Papanicolaou) if not bleeding 
*Colposcopy 
*Conization (subclinical tumor) 
*Punch biopsies (edge of gross tumor, four  quadrants) 
*Dilatation and curettage 
*Cystoscopy, rigid recto sigmoidoscopy(stages IIB, III, and IVA 
Radiographic Studies Standard 
  *Chest radiography 
  *Intravenous pyelography 
  *Barium enema (stages III and IVA and earlier           stages if there 
are symptoms referable to colon or rectum)  
Complementary 
   *Lymphangiography 
   *Computed tomography (CT) or magnetic resonance imaging 
(MRI) 
   *Positron emission tomography (PET) scan(optional) 
Lab tests    *Complete blood count including manual      platelets 
   *Biochemical evaluation including LFT and RFT  
   *Urine analysis 
   *blood born virus screening 
 
 
Laboratory studies 
Blood tests included serum for Biochemistry – creatinine and liver function tests, blood 
for Pathology-hemoglobin, total count with differentials, platelets, and Virology sample 
for Blood Borne Viruses, and  urine analysis. 
Radiological tests- Chest X-ray (PA), and intravenous pyelogram is recommended for all  
patients.  A colon barium enema is advised  for all patients with stage IIB and more 
advanced disease and in those patients who gives a history of urinary or lower 
gastrointestinal tract complaints.Those who afford can do USG abdomen and pelvis or 
CT or  MRI evaluation instead of the same.  
3.10 Prognosis 
 
According to statistics from the American Cancer Society, the five-year survival rate by 
stage is [88]: 
Stage IB – 80 percent 
Stage IIA – 63 percent 
Stage IIB – 58 percent 
Stage III – 30 percent 
Stage IVA – 16 percent 
3.11 TREATMENT 
 
Intraepithelial disease (cervical intraepithelial neoplasia[CIN]) is treated with superficial 
ablative techniques. 
3.8A. Early stage disease 
Stage Ia2 ( tumor with deep stromal invasion 3-5 mm and no greater than 7 mm diameter) 
and Ib1 (4 cm or less in size) are treated with radical hysterectomy and bilateral pelvic 
lymphadenectomy.  
 In selected patients with tumors less than 2 cm who are keen to preserve fertility, radical 
vaginal trachelectomy (removal of cervix, the upper part of the vagina, and parametrial 
tissue) and laparoscopic pelvic lymphadenectomymay be carried out. 
Stage Ib1 and IIA (tumor 4 cm or less) are treated equally effectively with 
radical surgery or combined radical EBRT and brachytherapy with both treatments giving  
80–90 per cent 5-year survival rates. 
Stage Ib2 or IIa tumors (>4 cm tumor size) have deep stromal invasion and 
an increased risk of parametrial and lymph node involvement. Surgery is performed in 
selected patients with large tumors, lymphovascular space invasion (LVSI) and 
adenosquamous or high grade histology, followed by postoperative radiotherapy. 
Ovarian transposition may minimize the chances of radiation-induced menopause. 
Primary radical radiotherapy is preferable for other stage Ib2 and IIA patients. 
This avoids the increased morbidity seen when surgery is followed by postoperative 
radiotherapy.  
Lymph node dissection 
 As the risk of lymph node metastases with stage IA1 squamous cell cervical carcinoma  
is low ( <1 percent)  lymphadenectomy is not recommended unless there is 
lymphovascular space invasion . 
For stage IA2 disease or microscopic IB1 disease (nonvisible, >5 mm in depth and ≤4 cm 
in greatest dimension), the risk of nodal metastasis is 2 to 8 percent and pelvic 
lymphadenectomy alone is generally sufficient since the risk for Para aortic nodal 
metastases is quite small. However, if pretreatment imaging shows positive Para aortic 
nodes or if pelvic nodes that are enlarged or fixed are encountered at surgery, frozen 
section should be performed. If metastases are confirmed, par aortic lymphadenectomy 
should be performed as well.   
For macroscopic stage IB1 and IIA1 tumors, a complete pelvic lymphadenectomy should 
be performed at time of hysterectomy. Paraaortic lymphadenectomy is performed at the 
surgeon’s discretion and when pelvic lymph nodes are enlarged or fixed. 
 
Adjuvant therapy indications — For women with early stage cervical cancer treated 
with a primary surgical approach, adjuvant therapy should be administered if final 
pathologic findings suggest they are at risk for disease recurrence.  
Intermediate-risk disease — Final pathologic criteria (sometimes referred to as Sedlis’ 
criteria) used to define women at intermediate risk includes the following 
 
• Presence of lymphovascular space invasion (LVSI) plus deep one-third cervical 
stromal invasion and tumor of any size 
• Presence of LVSI plus middle one-third stromal invasion and tumor size ≥2 cm 
• Presence of LVSI plus superficial one-third stromal invasion and tumor size ≥5 
cm 
• No LVSI but deep or middle one-third stromal invasion and tumor size ≥4 cm 
 
 
The risks of recurrence and death in the presence of these factors are up to 30 percent 
following surgery alone  
Treatment of intermediate-risk disease — adjuvant radiotherapy to decrease the risk of 
recurrence. 
 
The benefit of adjuvant RT was shown in a 2012 meta-analysis that compared adjuvant 
RT to no further treatment after hysterectomy in 397 women with early-stage cervical 
cancer (stage IB to IIA) [89]. Adjuvant RT resulted in: 
 
• A reduction in the risk of disease progression (RR 0.58, 95% CI 0.37-0.91). 
• No difference in the risk of death at five years (RR 0.84, 95% CI 0.3-2.36), 
although the wide confidence interval suggests the study was underpowered to 
assess survival. 
More toxicity, including serious (grade 3/4) hematologic toxicity (RR 2.38, 95% CI 0.63-
9.05) and gastrointestinal toxicity (RR 7.32, 95% CI 0.91-58.8) was noted in this study.  
 
 
Although limited data suggest that chemoradiation may improve the risk of recurrence, it 
remains unclear whether this will translate into an overall survival. A retrospective 
analysis of 129 patients with intermediate-risk disease treated over a 13-year period 
compared outcomes following treatment with platinum-based chemoradiation (n=89) or 
RT alone (n=40) . Compared to RT alone, chemoradiation resulted in a lower recurrence 
rate (9 versus 23 percent, p=0.049) and a trend towards improved PFS at five years (90 
versus 78 percent, HR 2.82, 95% CI 0.99-8.02). However, the authors reported there was 
no difference in OS between the treatment groups (though the median duration or the OS 
rate at five years was not reported).  
 
In the absence of supporting data to inform both the benefits and the risks of 
chemoradiation following hysterectomy in these patients, adjuvant radiotherapy is the 
line of management recommended at present.Results of ongoing clinical trials, such as 
GOG 263, which is a prospective evaluation of RT versus chemoradiation as adjuvant 
treatment in women with stage I or II cervical cancer is awaited.   
 
High-risk disease — Women are considered to be at high-risk if any of the following 
features (sometimes referred to as Peters’ criteria) are present at final pathologic review . 
 
• Positive surgical margins 
• Pathologically confirmed involvement of the pelvic lymph nodes 
•  involvement of the parametrium 
 
 
For women with high-risk factors, the recurrence risk is approximately 40 percent and the 
risk of death is up to 50 percent following surgery alone [90-92].  
Treatment of high-risk disease — Adjuvant chemoradiation is recommended for women 
at high-risk of recurrence. The benefits of adjuvant chemoradiation were shown in GOG 
109, in which 268 women who underwent a hysterectomy for early cervical cancer and 
were found to have high-risk disease [91,92]. These patients were randomly assigned 
treatment with RT (49.3 Gy in 29 fractions to a standard pelvic field) with or without 
chemotherapy (four cycles of cisplatin 70 mg/m2 on day 1, plus 5-fluorouracil [5-FU] 
1000 mg/m2 per day by continuous infusion for four days, every three weeks). With a 
median follow-up of 42 months, compared to chemoradiation with cisplatin and 5-FU, 
RT resulted in [90]: 
 
• Lower progression-free survival at four-years (63 versus 80 percent, respectively; 
hazard ratio [HR] 2.01, p=.003)  
• Lower overall survival at four years (71 versus 81 percent, respectively; HR 1.96, 
p=.007) 
• Less serious (grade 3/4) toxicity, including neutropenia , leucopenia, nausea , and 
vomiting. 
 
 
Given the toxicity associated with cisplatin and 5-FU in combination with RT, later 
administration of single agent cisplatin with RT instead was followed because it is used 
most frequently as primary treatment of locally advanced cervical cancer and is 
associated with less morbidity than cisplatin plus 5-FU. In addition, a retrospective 
analysis of 187 patients confirmed that single agent platinum-based chemoradiation 
resulted in significant improvements in the recurrence rate, progression-free, and overall 
survival compared to primary RT [93].  
Preliminary data suggest that more contemporary RT techniques administered 
postoperatively, such as intensity-modulated RT (IMRT), may achieve similar survival 
outcomes with an improved toxicity profile [94,95]. However, the results of clinical 
trials, such as the RT Oncology Group 0418 trial (RTOG 0418), is awaited to inform the 
role of postoperative pelvic IMRT as a treatment modality in early stage cervical cancer. 
 
3.8B Locally advanced disease 
 
Primary radiotherapy is the treatment of choice for locoregionally advanced disease with 
a careful balance of EBRT and brachytherapy to maximize dose to tumor and avoid 
normal tissues. 
 Five-year survival rates with radiotherapy alone for stage IIB, IIIB and IVA disease are 
65–75 per cent, 35–50 per cent and 15–20 per cent, 
respectively. Studies of combined chemoradiation with cisplatin _ 5FU have 
shown a 30–50 per cent decrease in risk of death from cervical cancer compared with 
extended field radiotherapy alone. However, the main draw back of this study was that 
patients with poor PS, impairedrenal function and Para-aortic node disease were 
excluded, which means these results are applicable to a selected population only. Similar 
good results have been shown with concurrent mitomycin and 5FU, but neoadjuvant 
chemotherapy shows no benefit when given before radiotherapy. Data from randomized 
trials show that cisplatin-based chemotherapy improves survival, and locoregional control 
mainly  in stage II disease. It is commonly delivered as a single agent, weekly during 
EBRT. 
The benefit of chemoradiation for women with locally advanced cervical cancer rather 
than RT alone was demonstrated in a 2010 meta-analysis [96]. Compared with primary 
RT, the use of chemoradiation resulted in: 
 
• A reduction in the risk of death (hazard ratio [HR] 0.69, 95% CI 0.61-0.77), 
which translated into a 10 percent absolute improvement in survival. The survival 
benefit associated with chemoradiation significantly decreased with increasing 
stage. For women with stage IB to IIA, IIB, and III to IVA cervical cancer, the 
five-year survival benefit was 10, 7, and 3 percent, respectively (p = 0.017).  
• A reduction in the risk of recurrence (HR 0.66, 95% CI 0.59-0.73), which 
translated into a 13 percent absolute improvement in progression free survival. 
There was no association between stage and disease free survival reported. 
• A reduction in the risk of local recurrence (odds ratio [OR] 0.59, 95% CI 0.50-
0.69) and a trend towards a reduction in distant metastases (OR 0.81, 95% CI 
0.65-1.01). This reduction was seen in trials using both platinum-based and non-
platinum based regimens. 
• Higher rates of serious (grade 3/4) adverse events including gastrointestinal 
toxicity (OR 1.98, 95% CI 1.49-2.63). 
 
 
Chemotherapy regimen — RT is usually administered with either single-agent 
cisplatin or the combination of cisplatin plus 5-fluorouracil (5-FU) for the treatment 
of cervical cancer.Weekly cisplatin (40 mg/m2) during RT [96-98] achieves similar 
outcomes to cisplatin plus 5-FU and has a better toxicity profile. This was 
demonstrated in a randomized trial of 155 women with stage IIB to IVA cervical 
cancer (without Para-aortic node involvement) who were randomly assigned 
treatment with RT plus either cisplatin or cisplatin plus 5-FU [97]. When compared to 
cisplatin plus 5-FU, treatment with cisplatin ,at a median follow-up of 39 months,  
resulted in :  
 
• A higher rate of completion of chemoradiation (71 versus 60 percent, 
respectively) 
• Less serious (grade 3/4) hematologic toxicity (26 versus 43 percent) 
• Similar complete response rate (91 percent in both arms) and overall survival 
rate at four years (67 and 70 percent) 
 
Whether cisplatin in combination with an alternative agent to 5-FU would improve 
survival outcomes is not clear. 
 A phase III trial that enrolled 515 women compared cisplatin alone to cisplatin plus 
gemcitabine during concurrent RT [99]. Women randomized to combination 
chemotherapy also received two additional 21-day cycles of cisplatin plus 
gemcitabine after completion of RT. With a median follow-up of three years, the use 
of cisplatin plus gemcitabine resulted in:  
 
• An improvement in progression free survival (PFS) compared to cisplatin 
alone (HR for progression 0.68, 95% CI 0.49 to 0.95; three-year PFS 74 
versus 65 percent)  
• An improvement in overall survival (OS, HR for death 0.68, 95% CI 0.49 to 
0.95) 
• But was associated with significantly more serious (grade 3/4) toxicities (87 
versus 46 percent) and rate of hospitalizations (30 versus 11) 
 
It is not clear whether the benefits of the investigational treatment were due to the use 
of cisplatin plus gemcitabine during RT or following chemoradiation.  
 
 
Treatment of Para-aortic nodes — Women with evidence of Para-aortic node 
involvement have a poor prognosis with a five-year survival rate of approximately 40 
percent .It is routine practice to treat these patients with extended field RT. There are no 
trials that compare chemoradiation using extended field RT (to cover the Para-aortic 
region) versus pelvic RT 
In the largest study, the Gynecologic Oncology Group enrolled 95 women with 
histologically confirmed Para-aortic node metastases and treated them with concomitant 
chemoradiation using extended field RT and reported the following results [104]: 
 
• The three-year overall and PFS rates  were  found to be 39 and 34 percent, 
respectively.  
• Comparatively low degree of  grade 3 or higher gastrointestinal toxicity ( 19 %), 
likely due to a lower dose to the Para-aortic region used in this study compared to 
the RTOG study. 
• The rate of late morbidity at four years was 14 percent. 
 
 
These data suggest that disease control can be attained in some women with locally 
advanced cervical cancer. However, treatment is associated with a high rate of acute and 
late toxicity.  
 
The role of elective para-aortic node irradiation is controversial with no survival 
advantage shown by the EORTC trial, but another study has reported 25–50 per cent long 
term survival after treatment for microscopic disease but with increased morbidity 
 
Importance of time to completion of chemoradiation — For all women undergoing 
chemoradiation, treatment should be completed within eight weeks. Although older 
studies demonstrated the importance of the timely completion of RT [100-102], there are 
limited data on the importance of time to completion for women undergoing 
chemoradiation [ 103]. In one series of 113 women with stage IB to IIIB disease, with a 
median follow-up of 26 months, time to completion of brachytherapy >56 days was 
associated with a higher rate of disease progression within the pelvis (26 versus 9 
percent, HR 2.8, 95% CI 1.2-16) [104]. However, the time to completion of 
chemoradiation was not a significant factor for distant disease progression or disease-
specific mortality. 
 
Any urinary tract obstruction should be corrected prior to cancer treatment, especially in 
patients who are otherwise candidates for primary chemoradiation. In a retrospective 
study performed by the Gynecologic Oncology Group involving 539 women with stage 
III cervical cancer (44 percent of whom presented with hydronephrosis) treated with 
chemoradiation, women who received treatment for ureteral obstruction had a 
significantly longer progression-free survival (PFS) and median overall survival (OS) 
than those in whom obstruction was not treated (PFS: median 18 versus 10 months; OS 
median 34 versus 17 months) [105].  
 
Where a vesico- or recto-vaginal fistula is present, a urinary diversion procedure or 
defunctioning colostomy should be performed prior to radiotherapy 
3.8c Stage IVB metastatic disease 
Short course pelvic radiotherapy is successful in relieving bleeding and pelvic pain in 
patients with metastatic disease. 
 Palliative radiotherapy is used to relieve pain from bone secondaries and symptoms from 
brain and nodal metastases. 
 
 
4.METHODS AND MATERIALS 
 
4.1Methodology 
 
Data was collected from May 2012 to May 2013.During this period,20 women with 
locally advanced biopsy proven squamous cell carcinoma cervix underwent,T2-weighted 
MRI in addition to planning CT scan were enrolled in this study. 
Approval from institutional research and ethics committeewas obtained.  
All suitable subjects were explained about the study, and were provided with the 
informed consent with details of the study. After reading it and the clarification of any 
doubts, they were enrolled into the study after obtaining their written informed consent . 
4.2Inclusion criteria 
 
The patients were screened for the following inclusion criteria and then enrolled.  
• Female patients of more than 18 years of age  
• Diagnosed to have squamous cell carcinoma cervix IIA- IIIB[ FIGO 
staging] 
• Being planned for treatment with radical chemo-irradiation  
• ECOG0-1 
• Willing to participate in the trial 
 
4.3Exclusion criteria- 
• previous irradiation to pelvis 
• other malignant disease 
 
4.4Patient workup 
 
The patients who fulfilled the inclusion and the exclusion criteria were selected 
for the study.   
The history and clinical examination findings was carried out 
 
4.5 Pre Treatment investigations: 
 
A cervical punch  biopsy was done  to confirm the diagnosis.   
 Blood tests— 
Renal Function Tests and  Liver Function Tests  
Complete Blood Counts 
Blood Borne  Virus screen 
Urine analysis--Microscopy / Culture  
Cystoscopy and Proctoscopy 
Radiological tests--Chest X-ray (PA), Ultrasonogram abdomen and pelvis  
Baseline ECG 
 
 4.6 Treatment simulation 
 
All patients underwent treatment simulation, prior to initiation of radiotherapy.  Patients 
either underwent conventional radiotherapy planning with conventional technique or 
conformal radiotherapy technique  (3DCRT, IMRT) . Immobilization with Vacloc was 
done in patients who were undergoing  conformal radiotherapy. Patients are simulated 
supine with arms on the chest, knees and lower legs immobilized, and anterior and lateral 
tattoos marked with radio-opaque material,aligned with lasers to prevent lateral rotation.  
.Planning CT scans were  taken from the level of diaphragm to 5 cm beyond the vaginal 
introitus. 
4.7 Imaging 
 
Imaging was performed in these 20 patients to assess tumor size, locoregional extent, and 
pelvic nodal status and these Images were used for radiotherapy planning. Intravenous 
contrast is used to outline pelvic blood vessels to be used as surrogates for pelvic nodes in 
CTV delineation. It may also enhance the GTV primary.Oral contrast was given to all 
patients to outline the bowel. 
MRI scans were performed on a 3-T MR scanner (Intera Achieva) according to 
Radiology department protocol for pelvic malignancies   , CMC Vellore. Axial T2 
weighted HR images were primarily assessed. Imaging parameters for the T2W HR 
images were given below .Repetition time  (TR) 3625 ms, echo time (TE)100 ms, echo 
train length 12, band width 21.78kHZ, field of view 32 cm, slice thickness 3 mm ,gap 
0mm,number of excitations 3,no phase wrap, matrix 352x293. 
 
 
4.8 Image registration 
 
T2 Weighted  MRI images were later fused to the planning CT scan for contouring .The 
image registration method used for fusion of planning CT scan with T2W  MRI  series is by 
Automatic image registration using DICOM coordinate system.This registration is done by 
aligning the origins of the DICOM coordinate system saved to the images by the imaging 
device. 
The images will be used to delineate the tumor volumes and OAR s on the treatment 
planning system[ ECLIPSE_ ARIA].  
4.9 Contouring  
 
Contouring of tumor volume and organs at risk were done  as per RTOG guidelines .The 
volumes  generated   GTV –gross tumor volume delineated on CT and MRI werer  compared 
. Accurate delineation of GTV , CTV and organs at risk  is an important advantage of image 
based planning. 
• GTV - Entire GTV; intermediate/high signal seen on T2-weighted MR 
images/enhanced lesion in cervix on CT imaging 
Comparison was done between  tumor volume ( GTV primary ) delineated by  these 
imaging modalities( MRI GTV p vs CT GTV p). 
4.10.Comparison between imaging modalities 
 
The investigational imaging MRI  was  compared with CT imaging to compare the target volume 
delineation and evaluate the impact of MRI on target volume as compared to the volumes 
obtained on a CT scan  in terms of assessment of  GTV Primary (Cervical tumour, involvement 
of uterus, vagina and parametrium) and GTV Lymph nodes. 
Study also looked at any change in the staging of the disease based on additional information 
form image   modalities  which will automatically change the management  and prognosis  in 
these patients. 
Attempt was done to  see if CT scan along with clinical findings can be a good 
alternate to MRI scan .Another objective was to  look at the possibility of 
reduction in treatment volume based on MRI when compared to CT based 
planning. 
Evaluation was also done to check the possibility of avoiding  invasive procedures 
like cystoscopy  based on MRI/CT findings. 
 
4.10 Treatment 
 
Patients either underwent treatment with radical chemoradiation or neoadjuvant 
chemotherapy followed by radical chemoradiation. 
 
4.11 First follow up evaluation 
 
The first follow up was done after 6 weeks. History of all the complaints and a thorough 
clinical examination is done.  The clinical evaluation was done to assess the tumor 
response as well as any toxicity.   
 
 
4.12 Statistical Analysis 
 
A descriptive analysis and frequency distribution of the patient characteristics was done.  
Fisher's Exact test was done to find out relationship between prognostic factors and 
image findings.PABAK was done to compare different imaging modalities (CT versus 
MRI). 
Paired T test was used for tumor volume comparison 
 
 
 
 
 
 
 
5.Results 
 
Twenty  patients, diagnosed  with locally advanced carcinoma cervix underwent planning 
CT scan  of abdomen pelvis and T2 Weighted MRI   pelvis . Data were collected and 
analyzed.  
5.1Demographics 
 
Most of the patients belonged to the age group between 40 to 50 years (12 out of 20 
patients).  Among them 2 patients   were below the age of 40 and 4 patients were in the 
age group of 50 to 60 years and 2 patients were above 60 years. 
5.2.Symptoms of primary disease 
 
The main presenting complaint was white discharge per vaginum  (13 out of 20 patients ) 
and bleeding per vaginum (11 out of 20 patients ) and low backache (10 out of 20 
patients ) 
5.3 FIGO staging 
 Among  20 patients , 15 were  clinically staged as FIGO stage IIIB and  5 patients 
belonged to FIGO stage IIB. 
Comparison between clinical and image findings based on USG abdomen pelvis, CT 
abdomen pelvis and MRI pelvis 
 
5.4 Primary tumor assessment 
 
Primary tumor assessment was done by clinical examination and different modalities of 
imaging like ultrasonography, CT abdomen pelvis and MRI pelvis.  
Assessment of  local extent of tumor based on clinical and imaging findings 
 
5.5.Vaginal involvement assessment 
stage IIIB
Stage IIB
 Clinical examination showed vaginal involvement in 19 out of 20 patients. Of these 19 
patients,MRI showed vaginal involvement in 18 patients and CT scan showed vaginal 
involvement in only 11 patients. There is good correlation between clinical examination 
finding and MRI. 
5.6Lower uterine segment involvement assessment 
 
MRI showed lower uterine segment involvement in 6 out of 20 patients and CT scan 
showed uterine involvement in only in one patient 
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5.7 Assessment of parametrial extension 
 
All 20 patients showed parametrial involvement on clinical examination, while MRI 
showed involvement in 18 patients.Clinically parametrial involvement was up to pelvic 
side wall in 15 out of 20 patients while this wasseen only in1 patient on MRI.The 
remaining 14 patients with clinical 3B disease there was bulky parametrial disease on 
MRI but this was not upto pelvic sidewall. 
 CT scan showed parametrial involvement in 18 of the 20 patients, not extending up to 
pelvic side wall,but it was difficult to makeout the extent of parametrial involvement on 
CT scan. 
5.8Assessment of pelvic lymphadenopathy 
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 Detection of pelvic lymphaedenopathy was assessed by  these imaging modalities and 
comparison was done between USG abdomen ,CT and MRI was done in only 17 patients 
as only 17 patients had undergone USG abdomen in our study.  Comparison was done 
between CT, abdomen and MRI pelvis  in detecting pelvic nodes in 20  patients. CT and 
MRI had similar findings and Ultrasonography under estimated pelvic 
lymphaedenopathy. 
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5.9 Assessment of para aortic nodes 
 
Comparison between CT scan and Ultrasonography of the abdomen only was done for 
the detection of paraaortic nodes as the patients had MRI of the pelvis only done.Among 
17 patients, who underwent CT and USG abdomen, CT scan detected para aortic nodes in 
2 which was not picked up on USG. 
5.10Assessment of metastatic disease 
 
Among the 17 patients who had USG abdomen pelvis and CT abdomen there  no 
evidence of  visceral  metastasis. 
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5.11 In assessing bladder involvement 
 
 
CT scan showed loss of fat plane with bladder in 2 patients and one of these patients had 
tumor abutting the bladder on MRI. Tumor abutting bladder was seen in 6 patients on 
both CT scan and MRI, 3 patients on CT scan only and 2 others on MRI only. 
Cystoscopy was normal in all these patients. There were 2 patients, one with bladder 
mucosal irregularity and another one with trigonal edema on cystoscopy,biopsy from the 
lesion was negative for malignancy. Imaging did not picked up these 2 changes.The 
patient with bladder mucosal irregularity had findings of tumor abutting bladder on MRI 
but normal findings on CT. 
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5.12 Target volume delineation based on CT and MRI 
 
 
Volume of cervical growth based on CT and MRI 
 Mean volume 
Tumor volume on CT scan 79.8 
Tumor volume on MRI scan 59.7 
Difference 20.02 
 
Mean volume  of  primary growth measured by  CT scan was 79.8 cm3 and MRI was 
59.7 cm3 with a difference of 20.02 cm3, which was statistically significant by  Paired t 
test 
 
5.13Posterior extent of the primary lesion 
 
Posterior extent of the primary lesion was upto the level of S2 and beyond in a total of 
18patients with 11 patients having tumour upto the level of  S2,6 patients up to the level 
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of S3 and 1 patient beyond S3. The position of the uterus was retroverted in one patient 
and was beyond the posterior border of the conventional four field box technique which 
was kept at S2/S3 junction. Therefore the conventional field would have resulted in gross 
tumour being beyond the target volume  in 12 patients,having inadequate tumour volume 
margin in 7 patients and therefore would have been inadequate in 19 out of 20 patients. 
 
5.14 Prognostic factors 
 
1.Significance of AP diameter more than 4 cm  and disease status. 
It was found that in  disease progression  in 6 out of  9 patients ,who had anteroposterior 
(AP) tumor diameter more than 4 cm . There was only 1 patient,who had disease 
progression out of 8 patients,with AP diameter less than 4 cm.Statistical analysis with 
Fisher,s exact- showed significant  p value (0.05).This showed significant association 
between anteroposterior diameter > 4cm with disease progression. 
2.Significance of tumor volume more than 50 mm3 and  disease progression 
 In 6 out of 12 patients with tumor volume more than 50 cm3 had disease 
progression,compared to only one out of 5 patints with tumor diameter less than 50 cm3 
had disease progression.  This Appears to be significant but was not statistically 
significant due to less number of patients. 
3.Relation ship between  tumor volume and nodal status. 
In 8 out of 15 patients with tumor volume more than 50 cm3 had  pelvic 
lymphaedenopathy,compared to only one out of 5 patints with tumor diameter less than 
50 cm3 .  This Appears to be significant but was not statistically significant due to less 
number of patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.DISCUSSION 
 
Uterine cervical neoplasm  is a major health problem in developing countries like India. 
Appropriate evaluation of disease extent and staging is important as this has an impact on 
the management, prognosis and outcome. 
The International Federation of Gynecology and Obstetrics is the most commonly used 
staging system for carcinoma cervix. Since the staging system should be uniform and 
feasible at all centres and also allow for comparison of results from different centres, 
FIGO has recommended staging to be based on clinical findings which  includes 
assessment of the tumour extent (ie, extent of local disease, tumor size, involvement of 
cervix, vagina, parametrium and extent into adjacent normal tissue like rectum and 
bladder)along with limited radiological investigations which does not include MRI and 
CT scans for staging in carcinoma cervix. Clinical staging may be adequate for 
evaluating local disease extent, but does not take in to account involvement of the uterus, 
lymph nodesor distant metastasis. It has been reported in literature that MRI is superior to 
CT scan and clinical examination for assessing the tumor size and involvement of the 
uterine body. 
As patients with carcinoma cervix belong to the lower socioeconomic strata where 
MRI/CT is not feasible and also as MRI/CT may not available in all centers it is not 
possible to do these routinely for staging and management. Hence evaluation in the form 
of less expensive imaging and thorough clinical examination would be a good alternate 
that could be carried out. Though the findings on CT, MRI, or PET examinations are not 
mandatory for FIGO staging it could be of additional benefit and provide extra 
information that would result in stage migration, help appropriate selection of  treatment 
modality (surgery/chemo-irradiation),essential for (result in) more accurate radiotherapy 
treatment planning and also provide prognostic information that would impact on the 
outcome of treatment and survival. Prognostic factors like stage at presentation , tumor 
diameter, tumor volume,lymph node metastasis,lymphatic vascular space invasion,deep 
stromal invasion, microscopic evidence of parametrial invasion , cell type and 
haemoglobin level, have an impact on survival .Therefore therevisedFIGO staging 2009 
has included imaging with MRI in addition to clinical stagingwhere resources permit. 
 
Primary tumor assessment 
It is advisable that all patients with carcinoma cervix should be jointly evaluated with 
detailed history and physical examination by the Radiation and Gynecologic oncologist. 
Examination under anesthesia provides better assessment of primary tumor in early stage 
disease. In all patients with stage IIB and more advanced disease and in those patients 
who give a history of urinary or lower gastrointestinal tract complaints ,cystoscopy  or 
rigid rectosigmoidoscopy is recommended to rule out local infiltration. 
In cervical cancer, tumor is visualized as a soft tissue mass on CT imaging,which often 
results in enlargement of the cervix. Generally there will be non-homogenous 
enhancement around the tumor following contrast administration with areas of necrosis 
and ulceration seen as hypodense areas within it. Evidence of parametrial soft tissue 
mass, any irregularity of the lateral margins of the cervix and obliteration of periureteral 
fat planes are indicators that suggest parametrial invasion, but these are not definitive 
indicators. Therefore it is difficult to make out parametrial infiltration on CT imaging. 
The ability of CT scan in assessing the tumor size is limited by poor soft tissue 
discrimination. Yang et al reported 85 %accuracy  for CT scan in assessing tumor size . 
T2 –Weighted MRI provides better description of cervical anatomy. The normal cervical 
stroma has  low signal intensity on T2 weighted images , and cervical tumors appears as 
high signal intensity compared to cervical stroma and can be easily differentiated from 
surrounding normal structures. In his study, Subak et al reported that, estimation of tumor 
size  by MRI was with in o.5 cm of the surgical sample in 93 % of patients (76). 
Donald et al(ACRIN6651 /GOG intergroup study) , in his study  comparing MRI, CT  
and clinical examination for delineating early cervical cancer,reported that MRI was 
superior to CT and clinical examination in assessing tumor size (109) . 
In a prospective study by Mitchell DG et al, which included 208 women, most with stage 
IB diseasewho underwent pretreatment  MRI and CT   [44],It was found that MRI 
correlated more closely with surgicopathologic findings than CT or physical examination. 
This study also showed that there was an overestimation of tumor size in both imaging  
modalities.Hricak H showed in his study that MRI  wasmore helpful in the assessment of 
extra cervical tumor  extension than CT scan (45). 
Study done by Hancke K, Heilmann, and  Bipat S  (50,51) shown superiority of MRI 
over CT scan in detecting parametrial involvement .MRI was found to be superior to CT 
for evaluation of parametrial involvement in a meta-analysis of 57 studies, done 
byBalleyguier C  et al (52)  . 
All 20 patientsshowed parametrial involvement on clinical examination, while MRI 
showed involvement in 18 patients.Clinically parametrial involvement was up to pelvic 
side wall in 15 out of 20 patients while this wasseen only in 1 patient on MRI.The 
remaining 14 patients with clinical 3B disease there was bulky parametrial disease on 
MRI but this was not upto pelvic sidewall. 
CT scan showed parametrial involvement in 18 of the 20 patients, not extending up to 
pelvic side wall, but it was difficult to make out the extent of parametrial involvement on 
CT scan. 
Thereforein our study thelocal tumor extent into parametrium was more on clinical 
assessment than what was detected on both imaging modalities. Between CT and MRI 
findings, the tumour was better seen on MRI and the findings correlated betterwith 
clinical findings than CT scan. 
Vaginal involvement 
Choi et al. (106) in his study among  23 patients ,pretreatment evaluation with MRI 
reported a sensitivity of 87.0% and a specificity of 79.0% with 3 false negative reports  
for detecting vaginal involvement.  In his study Sheu et al., (107)reported that, MRI 
identified vaginal involvement in 9 patients, with 2 false negative reports and  and 6 false 
positive reportswith  histological comparison. The sensitivity of MRI  was found to be  
82.0% and specificity 84.0% with histological comparison in this study.. 
In our study among the 19 patientswho had vaginal involvement clinically,MRI showed 
vaginal involvement in 18  patients and CT scan showed vaginal involvement in only 11  
patients. So detection of vaginal involvement with CT scan along with clinical 
examination would result in similar findings as MRI. 
 
Lower uterine involvement 
In a study by  Sahdevet al., (108) the efficacy of MRI in detecting lower uterine segment 
involvement was found to be superiorwith a  specificity of 99.0%.. In a comparative 
study by  Donald et al(ACRIN6651 /GOG intergroup study) showed MRI is superior to 
CT scan for evaluationg uterine body involvement (109). 
In our study, MRI was found superior to CT in detecting lower uterine involvement. MRI 
showed lower uterine segment involvement in 6 out of 20 patients and CT scan showed 
uterine involvement in only 1 patient. Detection of lower uterine segment involvement is 
important as this is associated with a bad  prognosis and this cannot be made out on 
clinical examination. 
 
Pelvic Lymph node detection  
The rate of detection of pelvic lymphadenopathy was compared  across all three 
modalities in 17 patients.  Comparison was done between CTand MRI   in  20  patients.  
CT and MRI had similar findings and Ultrasonography under estimated pelvic 
lymphaedenopathy. 
Stage migration based on imaging only in para aortic node detection 
 In a comparative study  by Heller et al (Gynecologic Oncology Group (GOG) protocol), 
Pre operative CT scan,Lymphangiography and ultrasonography was performed to assess 
para aortic adenopathy and later it was compared with  a histological reports of  Para-
aortic node dissection in patients whom had  negative staging studies (110).  False 
negative results for pelvic node evaluation was more with ultrasonography  (30%) and 
less for lymphangiography (14%).. The sensitivity and sensitivity  was high for for 
lymphangiography,  and less for for ultrasonography .This study recommended that 
ultrasonography,, is not  a reliable imaging  in preoperative detection of lymph node 
metastases. 
Multiple studies has shown that the  accuracy of CT scan in staging cervical cancer 
ranges from 63% to 88%.(27).  In the detection of lymph node  the accuracy is found to 
be 77% to85%. y of 93%(28).The CT scan is more valuable in evaluation of para aortic 
nodes  and Camilien et al in his study where pre operative CT scans were correlated with 
histopathological report collected by exploratory   laparotomy showed , 67 %  sensitivity  
and  100 % specificity  for CT scan in detecting para aortic nodes (111) . 
. 
In his study ,Hawnaur et al. compared pretreatment  examination under anesthesia 
(EUA), transrectal ultrasonography (TRUS), and MRI in assessing tumor volume and 
staging in  60 patients with invasive carcinoma of the cervix. It was found that  MRI was 
superior in assessing the  tumor extent  and lymph node enlargement when compared to 
TRUS and EUA. (112) 
According to  Chunget al., [113]  introduction of MRI has improved staging in cervical 
cancer patients. American College of Radiology Imaging Network (ACRIN) study (44)], 
reported that staging accuracy improvedfrom 30% - 40% to about 70%  with the 
introduction of MRI. 
Target volume delineation based on CT and MRI 
Accurate delineation of GTV and CTV is an important advantage of image based planning. 
Thus addition of MRI  is likely to give a better and more accurate tumor volume delineation 
which would in turn translate into appropriate dose to the tumor with more sparing of the 
normal tissues. It was also shown to  reduce geographical miss during treatment planning.   
A number of publications from the American College of Radiology Imaging Network and 
the Gynecologic Oncology Group have demonstrated that traditional T2-weighted MRI is 
superior to CT for tumor delineation in cervical cancer, mainly due to its high soft-tissue 
contrast for the evaluation of local tumor extension ( 44). 
In a study by Subak LL, showed that tumor volume was evaluated accurately by 
MRI,when compared to CT and which was  later confirmed by pathological evaluation .  
Computed tomography could not distinguish cancer from the surrounding normal cervical 
tissue  (116). 
 
In our study,mean volume  of  primary growth measured by  CT scan was 79.8 cm3 and MRI 
was 59.7 cm3 with a difference of 20.02 cm3, which was statistically significant by  Paired t 
test. The tumour was better seen and it was easy to delineate on MRI.Most of the time, it was 
difficult to make out tumor from surrounding normal cervical stroma with CT scan and 
therefore could have been overestimated. 3D Conformal radiotherapy uses a set of fixed 
radiation beams that are shaped using the projection of target volume   and have a uniform 
intensity across the field. The use of intensity modulated radiotherapy provides to confine the 
high dose portions of the radiation field to nontraditional shapes. IMRT has been shown to 
reduce normal tissue irradiation and has been associated with reduced acute and chronic 
toxicity compared with 3DCRT.  Accurate delineation of GTV and CTV is an important 
advantage of image based planning.Thus addition of MRI  is likely to give a better and 
accurate tumor volume delineation which would in turn translate into appropriate dose to the 
tumor with more sparing of the normal tissues 
Posterior extent of the primary lesion and change in conventional field borders based on 
imaging findings. 
The commonly used field borders for the lateral fields were the anterior aspect of the 
symphysis and the S2/S3 interspace. Ports defined by these guidelines will not always 
besuitable for the patients presenting with different stage and local extent of 
disease.Based on intra-operative measurements, Greer et al.opined  that the entire 
anterior sacral silhouette should be included in the lateral field  in patients with locally 
advanced carcinoma cervix,due to  posterior extension of the  tumor. (68) 
 
In a  prospective study  conducted on 34 patients with cervix carcinoma  Kim et al ,(69)  
simulated  all patients with  conventional four-fieldpelvic portals .Customized blocks 
were used to shield  the posterior wall of therectum and a part of small bowel using the 
barium silhouette of those organs. Following this CT scan was done to identify the tumor 
volume on each slice. It was found that  posterior margin coverage was ranging from 
39% to 50% only in the conventional as compared to CT  based planning. There were  
inadequate coverage  at the customized rectal block, and in the posterior  border on the 
lateral fields. With a median follow-up of 36 months, it was found that pelvic control for  
inadequate margins was 100% and 71% for stage IB, 88% and 50% for stage IIB. 
 
In 1992 Russell et al.,reported the value of pelvic MRI in determining the lateral fields of 
the four field box technique ( 70).It is proven that  MRI has the additional advantage in 
the  visualization  the anatomy of the pelvis in all the planes .It also provides a  better  
soft tissue delineation  and tumor depiction than CT scan[71-76].From their study, 
Russell and colleagues found that  using the  conventional lateral portals , the tumor 
volume wasadequately  covered  in  only 44% of patients  . There was incomplete 
coverage of the  uterine fundus in 62.5% and marginal miss in more than 50% of patients.  
In their study Zunino et al. found that due to uterusflexion and associated pathology like 
myoma, endometriosis and pyometra ,the lateral portals failed to involve PTV in  50% of 
cases (77). 
Posterior extent of the primary lesion was up to the level of S2 and beyond in a total of 
18 patients with 11 patients having tumour up to the level of  S2, 6 patients up to the level 
of S3 and 1 patient beyond S3. The position of the uterus was retroverted in one patient 
and was beyond the posterior border of the conventional four field box technique which 
was kept at S2/S3 junction.  Therefore the conventional field would have resulted in 
gross tumour being beyond the target volume  in 12 patients,having inadequate tumour 
volume margin in 7 patientsand therefore would have been inadequate in 19 out of 20 
patients. 
 
Target volume delineation was superior with MRI than CT scan. With CT scanthe pick 
up of nodal disease, evaluation ofbladder involvement,  rectalinvolvement and metastatic 
disease was similar to MRI and superior to ultrasound examination and the volumes 
obtained were larger than on MRI and so could be used along with good clinical 
examination as alternate to MRI where MRI is not feasible. 
Bladder infiltration  
In a retrospective study by Krestin GP, Hauser M et al, they compared 6 different 
imaging signs of focal bladder infiltration in 129 patients who underwent  CT and MRI 
examinations. These findings  were later correlated with cystoscopy, 
rectoscopy,intraoperative findings and histological examination of surgical sections 
(65).In 27 patients submitted to both imaging examinations  it was found that  MRI 
provided similar results as endoscopic procedures like  cystoscopy and rectoscopy 
.Subset analysis showed that MRI was superior to CT scan. This study showed that 
Imaging  can predict  bladder or rectalwall  infiltrationin carcinoma of the uterine cervix 
and can avoid  endoscopic procedures. 
In another study by Rockall AG, 5 point scoring system was done based on MRI findings 
to rule out bladder and rectal infiltration  and score of 3 or above were used to identify 
patients with bladder and rectal infiltration (66). This study showed that MRI  scoring 
system can predict local infiltration of bladder and can  avoid the need for invasive 
procedures like  cystoscopy in majority of patients with cervical cancer. This   leads to a 
reduction in morbidity associated with these procedures. 
In our study, cystoscopy was normal in 18 out of 20 patients. Among these 18 patients, 
CT scan  reported  loss of fat plane with bladder  in 2 patients andtumor abutting bladder 
was seen in 6 patients on both CT scan and MRI, 3 patients on CT scan only and 2 others 
on MRI only.  
There were 2 patients, one with bladder mucosal irregularity and another one with 
trigonal edema on cystoscopy, biopsy from these lesions was negative for malignancy.  
Both these patients had dysuria and increased frequency of urination and also urine 
microscopy showed increased number of RBC,s. The patient with bladder mucosal 
irregularity had findings of tumor abutting bladder on MRI but normal findings on CT 
and the patient with trigonal edema on cystoscopy, the imaging was not contributory. 
So MRI and CT may be adequate for evaluation of bladder involvement and could be an 
alternate method for majority of patients, with an invasive procedure like cystoscopy 
reserved for patients with urinary symptoms and who have findings of involvement or 
probable involvement on imaging. 
 
 
Prognostic factors based on Imaging 
Size of the cervical lesion  evaluated in CT scans were correlating with local control and 
overall survival .(25,26). In a retrospective study of CT scans done on cervical cancer 
patients by Shepherd et al showed that tumor depth was correlated with lymph node 
involvement(29). 
Based on MRI volume Kodaira et al showed that 5 year DFS of patients treated with 
radiotherapy with tumor diameter more than 5 cm was significantly lower (46.2%) than that 
for patients with size less than 5cm(88%)  (32) . 
Study done  by  Nihon Igaku  showed that tumor with craniocaudal diameter,(which was 
obtained by measuring the length of the tumor parallel to the long axis of uterine body ) was 
less than  or equal to 4 cm  was  associated with better five-year disease-free survival ( 70%) 
compared to patients with tumor diameter  more than 4 cm(35). 
Study   by Toita showed  that  antero posterior diameter (AP) of  tumor   more than4 cm  
was associated with increased incidence of lymph node metastasis and  distant 
metastasis.(36). 
In our study there was significant association between antero-posterior diameterof tumour 
of more than 4cm with disease progression. 
In another study by Kodaira et al, large tumor size (volume  more than 50 cm3 ) was 
associated with  positive lymph node enlargement  which inturn results in  unfavorable 
influence on survival  (p < 0.05) (37). In our study, mean volume of primary growth 
measured by CT scan was 79.8 cm3 and MRI was 59.7 cm3 . In 6 out of 12 patients with 
tumor volume more than 50 cm3 had disease progression,compared to only one out of 5 
patints with tumor diameter less than 50 cm3 had disease progression.  This appears to be 
significant but was not statistically significant due to less number of patients. 
 
 
 
 
7. Limitations of my study 
 
1.Sample size was small 
2.It was difficult to fuse CT axial images with T2W MRI images due to the following 
reasons 
• MRI was done in a different date where the bowel and bladder filling status were 
different 
• planning CT scan images were obtained with immobilization and CT markers in 
flat couch,where MRI was done by conventional method. 
• MRI images were  with 6 mm thickness and has been obtained in an angle 
perpendicular  to the axis of the uterus ,which was the departmental protocol for 
obtaining pelvic images ,where CT images were axial images with 5 mm 
thickness 
3.MRI imaging was confined to pelvis due to economic reasons in these patient where, 
MRI was done additional to CT abdomen pelvis . 
4.Biased sample collection. 
5.Tumor volume delineation -can have interpersonal variation. 
 
 
 
8. CONCLUSIONS  AND RECOMMENDATIONS 
 
In this pilot project done to compare T2 W MRI to CT imaging in volume delineation for 
radiotherapy planning in carcinoma cervix,showed that imaging modalities have a role in 
accurate delineation of  gross tumor volume (GTV). 
Though the findings on CT, MRI, or PET examinations are not mandatory for FIGO 
staging it could be of additional benefit and provide extra information that would result in 
stage migration, help appropriate selection of treatment modality, result in more accurate 
radiotherapy treatment planning and also provide prognostic information that would 
impact on the outcome of treatment and survival.  
Image based planning would in turn translate into appropriate dose to the tumor with 
more sparing of the normal tissues. It would also reduce geographical miss during 
treatment planning. 
MRI appears to be better than CT for locoregional disease assessment especially for 
primary tumor and adjacent soft tissue extension. 
CT with good clinical examination could be used as an alternate to MRI where MRI is 
not feasible. 
Bowel and bladder preparation are required before CT and MRI for better fusion with 
more accurate delineation of target and OAR. 
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 APPENDIX 1 :  Proforma 
 
Comparison  of T2 W MRI to CT imaging in volume delineation for radiotherapy 
planning in  locally advanced carcinoma cervix patients 
---------------------------------------------------------------- 
Name:                                           Age:                                                                      
Hospital No:                               RT no: 
Adress: 
Phone number: 
Presenting complaints 
• White discharge PV  Yes (1)/  No (2) 
• Bleeding  PV                 Yes (1)/  No (2)   
• Post Coital Bleeding  Yes (1)/  No (2)      
• ow  Backache   Yes (1)/  No (2)           
•  Abdominal pain                 Yes (1)/  No (2)           
• Bowel symptoms                       Yes (1)/  No (2)       
•  Bladder Symptoms               Yes (1)/  No (2)       
 
Medical comorbidities 
Diabetis mellitus                       Yes (1)/  No (2) 
Hypertension                             Yes (1)/  No (2) 
 
Pulmonary tuberculosis               Yes (1)/  No (2) 
Cardiac comorbidities                  Yes (1)/  No (2) 
 
Renal dysfunction                        Yes (1)/  No (2) 
 
Any chronic illness                        Yes (1)/  No (2) 
Past history of abdominal surgery   Yes (1)/  No (2)     
 
   Examination findings 
Height :          cm.      Weight:    Kg 
BSA:        Estimated creatinine clearance: 
• Pallor-                     Yes (1)/  No (2) 
• Pedal edema              Yes (1)/  No (2) 
• Nodes-   inguinal        Yes (1)/  No (2) 
•  Neck nodes               Yes (1)/  No (2) 
Per abdominal 
• Scar of previous surgery Yes (1)/  No (2) 
• Liver                                Yes (1)/  No (2) 
• Free fluid                        Yes (1)/  No (2) 
 
PV/PS/PR 
Cervix  
clinical volume -AP xCC xRL 
cervix - 1)Anterior 2)posterior3)both lips of cervix 
Growth  1) exophytic  2)   Ulcerative 
3)Infiltrative 
Fornices-1)Left lateral 2)right lateral 
3)anterior  4)posterior  5)all 
Vagina   1)Upper 1/3rd    2) Upper 2/3rd    
                      3) Lower1/3 rd 
RV septum   1)yes      2)no 
Parametrium 
Right-  1)Not up to pelvic side wall 2)Upto   
pelvic side wall  3)not involved 
Left-   1)Not up to pelvic side wall 2)Upto  
pelvic side wall 3)not involved 
Cystoscopy  1)bladder infiltration 2)trigonal edema 3)normal 
Proctoscopy   1)Rectal mucosal infiltration 2)Normal 
Final diagnosis-  
Carcinoma cervix stage 1) I 2)IIA 3)IIB 4)IIIA 5)IIIB 6)IVA 7)IVB 
USG abdomen 
tumor volume -             APxCCxRL 
Nodes-                               1)yes      2)no 
Hydroureteronephrosis     1)yes      2)no 
Liver metastasis                 1)yes      2)no 
CT ABDOMEN PELVIS 
Tumor size           APxCCxRL 
Extension to parametrium 1)yes      2)no 
Parametrial involvement  1)Not up to pelvic side wall 
2)Upto pelvic side wall  3)not involved 
Extension to vagina  1)yes      2)no 
Bladder infiltration  1)yes      2)no 
Infiltration of rectum 1)yes      2)no 
Mesorectal infiltration 1)yes      2)no 
Uterine involvement 1)yes      2)no 
Distal metastasis   1)yes      2)no 
Superior extend   1)L4  2)L5 3) S1 4) S2 5) S3 6) Below S3 
Posterior extend 1)S1 2)S2 3)S2p 4)S3 5)S3p  
Position-1)Anteverted 2)retroverted 
MRI PELVIS  
Extension to parametrium 1)yes      2)no 
Parametrial involvement  1)Not up to pelvic side wall 
2)Upto pelvic side wall  3)not involved 
Extension to vagina  1)yes      2)no 
Bladder infiltration  1)yes      2)no 
Infiltration of rectum 1)yes      2)no 
Mesorectal infiltration 1)yes      2)no 
Uterine involvement 1)yes      2)no 
Distal metastasis   1)yes      2)no 
Superior extend   1)L4  2)L5 3) S1 4) S2 5) S3 6) Below S3 
Posterior extend 1)S1 2)S2 3)S2p 4)S3 5)S3p  
Position-1)Anteverted 2)retroverted 
Nodal status 
CT abdomen plevis 
Para aortic            1)yes      2)no 
Common iliac        1)yes      2)no 
External ilac          1)yes      2)no 
Internal iliac          1)yes      2)no 
inguinal                  1)yes      2)no 
pre sacral              1)yes      2)no 
 
MRI pelvis 
External ilac          1)yes      2)no 
Internal iliac          1)yes      2)no 
inguinal                  1)yes      2)no 
pre sacral              1)yes      2)no 
Others 
Hydroureteronephrosis     1)yes      2)no 
Distant metastasis               1)yes      2)no 
 
Tumor volume delineation  
CT  
                 GTV Primary   -Volume in cm3 
                  CTV primary -Volume in cm3 
MRI  
                  GTV Primary   -Volume in cm3 
                  CTV primary -Volume in cm3 
Disease status on follow up 
 
1)Disease free 
2)Residual disease 
3)Local recurrence 
4)Nodal recurrence 
5)distant metastasis 
6)lost follow up 
Comparative volume between CT and MRI 
CT-GTV vs MR-GTV 
CT-CTV vs MR-CTV 
 
 
 
 
 
 
 
 
 
 APPENDIX  II : Protocols 
 
FiGO staging  (Fig.3) 
Stage 0-The carcinoma is confined to the surface layer (cells lining) of the cervix. Also 
called carcinoma in situ (CIS). 
Stage I -The carcinoma has grown deeper into the cervix, 
IA Invasive carcinoma which can be diagnosed only by microscopy, with deepest 
invasion <5 mm and the largest extension <7 mm  
 IA-1 Measured stromal invasion of <3.0 mm in depth and extension of <7.0 mm 
 IA-2 Measured stromal invasion of >3.0 mm and not >5.0 mm with an extension 
of not >7.0 mm 
 IB  Macroscopic lesions limited to the cervix uteri or pre-clinical cancers greater than 
stage IA  
 IB-1 Clinically visible lesion <4.0 cm in greatest dimension 
 IB-2 Clinically visible lesion >4.0 cm in greatest dimension 
 Stage II-Cervical carcinoma that infiltrates beyond the uterus, but involving  pelvic 
wall or to the lower third of the vagina  
 IIA Without parametrial invasion  
 IIA-1 Clinically visible lesion <4.0 cm in greatest dimension 
 IIA-2 Clinically visible lesion >4.0 cm in greatest dimension 
 IIB With obvious parametrial invasion 
 Stage III-The tumour spread to the pelvic side wall and/or involves lower third of the 
vagina and/or causes hydronephrosis or non-functioning kidney  
 IIIA Tumour infiltrates lower third of the vagina, without extension to the 
pelvicside wall 
 IIIB  Tumor extension to the pelvic sidewall and/or hydronephrosis or non-
functioning kidney 
Stage IV-The carcinoma has extended beyond the true pelvis or has involved (biopsy 
proven) the mucosa of the bladder or rectum. A bullous oedema, as such, is not considered as 
Stage IV  
IVA Infiltrating adjacent organs 
IVB  distant metastases 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX  III : FIGURES 
 
 
 
 
Figure .1     Anatomy of female pelvis -Sagittal view 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.Lymphangiogram for pelvic lymphnodes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3 .Diagrammatic representation of various anatomic stages of carcinoma of the  
uterine cervix, according to the Federation of Gynecologists and Obstetricians  
classification. 
 
 
 
 
 Fig.4 
Diffusion- weighted imaging in the abdomen and pelvis; concepts and 
applications 
RadioGraphics 2009; 29:1797–1810 • Published online 
10.1148/rg.296095521 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 APPENDIX IV : Information sheet for participants 
 
Study title:- A prospective study to compare T2 W MRI to CT imaging in volume 
delineation for radiotherapy planning in carcinoma cervix  
 
Name-   
 
It is for   the information that you have been diagnosed to have Cancer of the 
cervix stage_______ (FIGO).  The current recommended therapy is concurrent chemo 
radiation with weekly administered Cisplatin followed by brachytherapy. 
 
We are inviting you to participate in the study conducted in the Dept. of Radiation 
Oncology Unit II, Christian Medical College, Vellore in patients with carcinoma of the 
cervix. 
 
You are hereby being requested to participate in the above mentioned study.  
1.What is the study all about- The standard followed in our institution for the image based 
external beam radiotherapy for carcinoma cervix is CT scan based. However RTOG and other 
professional bodies use and recommend the use of MRI in addition of CT scan for the same. 
However, this is costly and all patients are unable to afford the same. The study attempts to 
determine if  MRI do significantly change the treatment 
  
2. What will be done? –Patients recruited in this study will undergo additional MRI evaluation   
based on the  additional  information the treatment plan may get modified. The MRI images will 
be fused with CT images which will give more soft tissue delineation. The fused MRI with CT 
will be used for treatment plan to be generated for the plan to be used for treating the patient. 
This is the standard of care as prescribed by RTOG.  
3.Description of any reasonably foreseeable risks or discomforts to the Subject- 
All contrast studies are associated with a small risk of drug reaction. If patient is asthmatic or 
have allergies, steroids and antihistamines will be given prior to the procedure. If patient had a 
previous contrast reaction   ,contrast study will be avoided. 
MRI –Patients with pace makers, cochlear implants, some type of aneurysm clips and implanted 
drug infusion devices or with suspected metallic injury anywhere in the body cannot undergo 
MRI evaluation. 
4 Is there any benefit in getting enrolled in the study? 
Additional imaging helps in better tumor volume delineation, which in turn helps in 
maximum dose delivery to the target volume with minimal toxicity to the normal tissues and 
reduced chance of geographical miss. Depending on additional information,  The plan of 
management may change, which is expected to benefit the patient. 
1. Disclosure of specific appropriate alternative procedures or therapies available to the 
Subject. 
Patient can be treated with information based on CT scan alone in case of CT based 
planning. 
 
6. What about the data security-  
              The data so collected will only be used for research purpose and not any other 
purpose and will not be supplied to any person or body except those authorised 
(investigators, institutional review board, ethics committee, professional bodies or 
any legal authorities whenever required). However, in any matter, your identity 
will be protected and will not be revealed. 
7. Trial treatment schedule(s) and the probability for random assignment to each 
treatment (for randomized trials) 
There is no provision of any randomisation. 
8. Compensation and/or treatment(s) available to the Subject in the event of a trial-related 
injury 
 We are not adding or removing any component of your treatment, therefore the 
possibility of treatment for trial related injury does not arise. 
9. An explanation about whom to contact for trial related queries, rights of Subjects and 
in the event of any injury 
For any trail related querries the principal investigator  Dr.Aparna can be 
contacted at 0416 228 2046 or 9176950471 
10. Monetary considerations-  
No money or compensation in any form will be given for participating in this 
study  
11. Subject’s responsibilities on participation in the trial- 
The subject’s responsibility in this trial is limited to undergo the treatment as per 
medical advice and undergo tests as required and answer the questionnaire at 
scheduled time. The patient is also expected not to delay inordinately in his/her 
follow up.  If the patient refuses to undergo any of the diagnostic tests ,  after 
clearing any doubts about the tests or regarding the study , she will deemed to 
have expressed her desire to be excluded form the study and will be regarded as 
been withdrawn from the study 
12. Participation-  
The participation is purely voluntarily. No monetary compensation or otherwise 
will be provided 
Can I leave the study-?  
In this study your treatment will be the same as the recommended   practice .  You 
are free to withdraw from this study at any point of time.  We assure that withdrawal 
from the study will not affect the rest of your treatment in any way and it will be 
continued as per the recommended treatment. 
1.2 Additional elements, which may be required  
a. Foreseeable circumstances under which the Subject’s participation may be terminated 
by the Investigator without the Subject’s consent. 
If you are found to have any condition that prevents you from undergoing any of 
the required tests, [ CT / MRI] your participation in the study will be deemed to 
be terminated.   However in any such situation, you will continue to have 
appropriate standardised care at per with all other trial and non-trial patients.  
b. Additional costs to the Subject that may result from participation in the study: 
As a participant of the study you will be asked to undergo some additional tests. 
The tests are expected to cost Rs-5610 INR.  Extra cost incurred  due to the study  
will not be bound to the patient.  
c. The consequences of a Subject’s decision to withdraw from the research and 
procedures for orderly termination of participation by Subject. 
As mentioned earlier, you can withdraw, from the study any moment you wish to. 
You would not be asked to furnish any reason neither your treatment nor follow 
up would get affected. However, we would like to hear from you the reasons if 
you please, and clear any doubts that may have risen.  
d. Can I know about my results-?  
             Surely, you will be provided with the results. Under no circumstances any 
information of your problem will be concealed from you. 
 e. Any treatment with radiotherapy or chemotherapy involves risks to fetus or embryo, 
and therefore we would ask you to confirm that you are not pregnant at time of the 
treatment and take appropriate contraceptive measures to prevent pregnancy during 
the treatment and till at least for the next follow up, if you were on chemotherapy.  
Nursing mothers are advised not to wet nurse the baby till all chemotherapy is over 
and till 1
st
 follow up. 
This is applicable to all patients undergoing radiotherapy or chemotherapy 
irrespective of the fact that you are a part of the trial or not. Even if you wish to 
withdraw from the trial, these precautions are to be taken. 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: 
_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 Signature of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name of the Witness: _____________________________ 
 
Informed consent form 
Study Title: A prospective study to compare T2 W MRI to CT imaging in volume 
delineation for radiotherapy planning in carcinoma cervix  
Study Number:   
Subject’s Initials _________             Subject’s Name: _________________________ 
Date of Birth____/____/______(DD/MM/YYYY) / Age: _______yrs  
Please initial box  
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ for 
the above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
APPENDIX V-DATA SHEET 
 
sno name age hno cervix growth forni vagina rvsep rtpara ltpara cystosco proctos findiag nodes1 hydrour livermet ctextparammtextparamctinvolv mrinvolv ctvagina mrvagina ctbladin mrbladin ctrectal mrrectal ctmesrec mrmesrec ctuter mruter ctdismet mrdismet ctparaaor mrparaaor ctcomili mrcomili ctextili mrextili ctintili mrintili ctinguin mringuin ct mrpresac cthydrou mrhydrou ctpyomet mrpyomet ctgtvp mrgtvp ctctvp mrctvp follow up
1 Gajalakshmi 42 210992F 3 1 5 2 2 2 2 3 2 5 4 2 2 1 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 64.16 24.24 188.67 168.24 1
2 Settuammal 49 242244F 3 1 5 1 2 2 2 3 2 5 4 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 107.57 76.85 280.06 262.07 3
3 SUSILA 45 245484F 3 1 5 2 2 1 2 3 2 5 4 2 2 1 1 2 2 1 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 205.36 134.48 455.78 462.01 1
4 GAYATRI DEVI 65 250616F 3 3 1 1 2 1 1 3 2 3 4 2 2 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 1 2 1 2 1 2 2 2 2 1 2 69.24 54.69 272.78 305.53 1
5 ZOTHANSANGI 43 215453F 3 2 5 1 2 2 3 2 5 4 2 2 1 1 2 2 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 54.96 53.15 465.11 347.74 2
6 THARA 47 171163F 3 2 1 1 2 1 1 3 2 3 4 2 2 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 16.45 5.16 123.83 112.4 1
7 SUNAY DEVI 51 312082F 3 3 5 2 2 2 2 3 2 5 4 2 2 1 1 2 2 1 1 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 28.46 18.06 179.35 158.66 6
8 SHANTHA 46 330536F 3 2 5 1 2 1 2 3 2 5 4 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 22.84 16.68 105.87 82.44 1
9 EASWARI 48 309560F 3 2 5 2 2 2 2 3 2 2 2 2 2 1 1 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 48.35 28.61 247.63 214.47 1
10 KALA 36 339870F 3 2 5 2 2 1 2 3 2 5 4 2 2 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 64.04 41.16 293.27 282.06 1
21 PODDUTUR JAYALAKSHMI46 295500F 3 1 5 1 2 2 2 3 2 5 2 1 2 1 1 2 2 1 1 2 2 1 2 1 2 2 1 2 2 2 2 2 2 1 1 2 1 2 2 2 2 1 1 2 2 219.96 165.25 546.75 545.37 4
22 AMBIKA DEVI AGARWAL41 471165F 3 1 5 3 2 2 2 3 2 5 4 2 2 2 1 3 2 1 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 165.78 209.6 335.82 400.39 2
23 KASTHURI SEKAR 57 785577C 3 1 5 1 2 2 1 3 2 5 4 2 2 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 1 1 1 1 1 2 2 2 2 2 2 2 2 1 1 46.74 37.66 215.69 200.11 5
24 JYOTHI 42 233999F 3 3 5 1 2 1 2 3 2 5 4 2 2 1 1 2 2 2 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 47.76 44.03 316.61 270.88 6
25 BHARATHI D 41 329328F 3 3 5 2 2 2 2 3 2 5 4 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 59.25 33.34 257.83 236.3 1
26 SELVI R 34 531107B 3 2 5 1 2 2 2 3 2 5 4 2 2 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 131.93 93.43 329.24 320.28 2
27 SABITRI SHARMA 61 410416F 3 1 5 1 2 1 2 3 2 7 4 2 2 1 1 2 2 2 1 2 2 2 2 2 1 2 1 2 2 1 2 1 2 1 1 2 2 2 2 2 2 2 1 1 45.06 31.83 259.85 235.98 5
28 DHANAM A 53 619071F 3 1 5 1 2 2 1 3 2 5 4 2 2 1 1 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 61.55 38.15 246.94 232.72 1
29 DEIVANI 51 370860A 3 1 5 2 1 1 3 2 3 4 2 2 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 15.29 9.4 106.29 120.53 1
30 RAMANI 44 171946F 3 3 5 1 2 3 1 3 2 3 4 2 2 2 2 3 3 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 121.76 80.19 211.47 217.13 6
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